

RAAJ MEDISAFE INDIA LIMITED

Regd. Office: 75/2 and 3, Industrial Area, Maksi Road, Ujjain-456010
Email: raajmedisafe@gmail.com, Website: www.raajmedisafeindia.com
Phone: 0734 2518989 2513349

September 2, 2025

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

SCRIP CODE: 524502, ISIN: INE548H01015

Re: **ANNUAL REPORT – 2024-25**

This is to inform you that 40th Annual General Meeting of the members of the Company is scheduled to be held on Thursday, the 25TH day of September, 2025 at 3.00 P.M. through Video Conferencing/OAVM.

Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are submitting herewith Annual Report of the Company for the Financial Year 2024-25 including copy of the Notice convening the 40th Annual General Meeting. The Annual Report is also available on the website of the Company **www.raajmedisafeindia.com**.

The Company has made necessary arrangements to provide remote e-voting facility to its members and also to Attend the aforesaid Annual General Meeting through Video Conferencing/OAVM and also to cast their votes on all resolutions set out in the Notice of 40^h Annual General Meeting by electronic means ("e-voting") for which necessary facility is being provided by Central Depository Services India Limited (CDSL)

Kindly acknowledge and take the same on record.

Thanking you,

Yours faithfully,
FOR RAAJ MEDISAFE INDIA LIMITED

ARPIT BANGUR
CHAIRMAN
DIN:02600716

Encls: As stated.

RAAJ MEDISAFE INDIA LIMITED

L33112MP1985PLC003039

**40th ANNUAL REPORT
2024-25**

Board of Directors

Shri Arpit Bangur
Shri Navin Jhavar
Smt. Krishna Jajoo

Managing Director
Jt. Managing Director
Non-Executive Director

Shri Rakesh Agrawal
Shri Hemant Kasliwal
Shri Ateet Agrawal

} Non-executive Independent
Directors

Key Managerial Personnel

Shri Sachin Sarda

Company Secretary &
Compliance Officer

Auditors

M/s. V.K. Ladha & Associates

Registered Office

75/2 & 3, Industrial Area,
Maksi Road,
Ujjain-456010
CIN: L33112MP1985PLC003039
Tel: 0734 2518989/2513349
Email: raajmedisafe@gmail.com
Website: www.raajmedisafeindia.com

Registrar & Transfer Agents

Ankit Consultancy Pvt. Ltd.
60, Electronic Complex,
Pardeshipura,
Indore-452010
Tel: 07314949444
Email: investor@ankitonline.com

**40th Annual General Meeting on Thursday, the 25th Day of September, 2025 at 3.00 PM
Through Video Conferencing/Other Audio Visual Means**

This Annual Report can be accessed at www.raajmedisafeindia.com

NOTICE OF 40th ANNUAL GENERAL MEETING

Notice is hereby given that **40th Annual General Meeting** of the Members of **Raaj Medisafe India Limited**, will be held on Thursday, the 25th day of September, 2025 at 3.00 P.M. through video conferencing/OAVM to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2025 including Audited Balance Sheet as at March 31, 2025, Statement of Profit & Loss Account and Cash Flow statement for the year ended on that date and the reports of the Board of Directors and Auditors thereon and in this regard, to pass the following resolution as **Ordinary Resolution**:

"RESOLVED THAT the audited Financial Statements of the Company for the year ended March 31, 2025 including Audited Balance Sheet as at March 31, 2025, Statement of Profit and Loss account and Cash Flow Statement for the year ended on that date and the reports of the Board of Directors and Auditors thereon laid before this meeting, be and are hereby considered and adopted."

2. To appoint Shri Navin Jhawar (DIN: 08729821), who retires by rotation, and being eligible offers himself for re-appointment as a Director and in this regard, to pass the following resolution as Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013, Shri Navin Jhawar (DIN: 08729821), who retires by rotation at this meeting and being eligible has offered himself for re-appointment, be and is hereby appointed as a Director of the Company, liable to retire by rotation."

3. To consider and if thought fit, to pass the following resolution as **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of section 139, 141 and all other applicable provisions of Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and based on the recommendation of Audit Committee and the Board of Directors, M/s. GDK & Associates, (Firm Regn. No.002159C), Chartered Accountants, Indore, who have given their consent and from whom eligibility certificate under section 141 has been received, be and are hereby appointed as Statutory Auditors of the Company for a period of 5 (Five) years to hold office from the conclusion of this 40th Annual General Meeting till the conclusion of the 45th Annual General Meeting of the Company in place of M/s. V.K. Ladha & Associates, (Firm Regn. No.002301C), Chartered Accountants, Ujjain whose First Term of Office as Statutory Auditors shall be up to the conclusion of this 40th Annual General Meeting.

RESOLVED FURTHER THAT the remuneration of the new auditors shall be such that as may be agreed upon between the Board of Director or any Committee thereof and them plus GST and actual out of pocket expenses as may be incurred in connection with the audit of the Books of Account of the Company.

SPECIAL BUSINESS:

4. To consider and if thought fit, to pass the following resolution as **Special Resolution**:

"RESOLVED THAT pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 204 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), on the basis of the recommendations of the Audit Committee and approval of the Board of Directors, the consent of the members be and is hereby accorded for appointment of Shri Manish Maheshwari (M.No. FCS 5174 and COP No. 3860) of M/s. M. Maheshwari & Associates, Practicing Company Secretaries (Firm Reg, No. U.C.N.I2001MP213000), as Secretarial Auditor of the Company from Financial Year 2025-26 till 2029-30, on such terms and conditions including remuneration as may be fixed by the Board of Directors of the Company."

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary, including but not limited to, finalizing the terms and conditions, settling all such issues, questions, difficulties or doubts whatsoever that may arise without being required to seek further consent from the Members and that the Members shall be deemed to have accorded their consent thereto expressly by the authority of this Resolution.

5. To consider and if thought fit, to pass the following resolution as **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Regulations 23(4) and any other applicable provisions under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), as amended from time to time, Section 2(76) and other applicable provisions of the Companies Act, 2013 (‘Act’) read with the Rules framed thereunder [including any statutory modification(s) or re-enactment(s) thereof for the time being in force] and other applicable laws / statutory provisions, if any, the Company’s Policy on Related Party Transactions as well as subject to such approval(s) consent(s) and/ or permission(s), as may be required and based on the recommendation of the Audit Committee, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’), which term shall be deemed to include the Audit Committee or any other Committee constituted / empowered / to be constituted by the Board from time to time to exercise its powers conferred by this Resolution) for the Material Related Party Transaction(s) / Contract(s) / Arrangement(s) / Agreement(s) entered into / proposed to be entered into (whether by way of an individual transaction or transactions taken together or a series of transactions or otherwise), as mentioned in detail in the Explanatory Statement annexed herewith, between the Company and Shriji Polymers (India) Limited (‘Shriji’) on such terms and conditions as may be mutually agreed between the Company and Shriji, for an aggregate value not exceeding Rs. 1400 Lakhs during FY25-26, provided that such transaction(s) /contract(s)/ arrangement(s) / agreement(s) is/are being carried out at an arm’s length pricing basis and in the ordinary course of business.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary, including but not limited to, finalizing the terms and conditions, settling all such issues, questions, difficulties or doubts whatsoever that may arise and to take all such decisions from powers herein conferred; and delegate all or any of the powers herein conferred to any Director, Chief Financial Officer, Company Secretary or any other Officer / Authorised Representative of the Company, without being required to seek further consent from the Members and that the Members shall be deemed to have accorded their consent thereto expressly by the authority of this Resolution.

RESOLVED FURTHER THAT all actions taken by the Board in connection with any matter referred to or contemplated in this Resolution, be and are hereby approved, ratified and confirmed in all respect.”

6. To consider and if thought fit, to pass the following resolution as **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Regulations 23(4) and any other applicable provisions under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), as amended from time to time, Section 2(76) and other applicable provisions of the Companies Act, 2013 (‘Act’) read with the Rules framed thereunder [including any statutory modification(s) or re-enactment(s) thereof for the time being in force] and other applicable laws / statutory provisions, if any, the Company’s Policy on Related Party Transactions as well as subject to such approval(s) consent(s) and/ or permission(s), as may be required and based on the recommendation of the Audit Committee, consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’), which term shall be deemed to include the Audit Committee or any other Committee constituted / empowered / to be constituted by the Board from time to time to exercise its powers conferred by this Resolution) for the Material Related Party Transaction(s) / Contract(s) / Arrangement(s) / Agreement(s) entered into / proposed to be entered into (whether by way of an individual transaction or

transactions taken together or a series of transactions or otherwise), as mentioned in detail in the Explanatory Statement annexed herewith, between the Company and Shriniwas Polyfabrics and Packwell Private Limited ("Polyfab") on such terms and conditions as may be mutually agreed between the Company and Polyfab, for an aggregate value not exceeding Rs. 1600 Lakhs during FY25-26, provided that such transaction(s) /contract(s)/ arrangement(s) / agreement(s) is/are being carried out at an arm's length pricing basis and in the ordinary course of business.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do and perform all such acts, deeds, matters and things, as may be necessary, including but not limited to, finalizing the terms and conditions, settling all such issues, questions, difficulties or doubts whatsoever that may arise and to take all such decisions from powers herein conferred; and delegate all or any of the powers herein conferred to any Director, Chief Financial Officer, Company Secretary or any other Officer / Authorised Representative of the Company, without being required to seek further consent from the Members and that the Members shall be deemed to have accorded their consent thereto expressly by the authority of this Resolution.

RESOLVED FURTHER THAT all actions taken by the Board in connection with any matter referred to or contemplated in this Resolution, be and are hereby approved, ratified and confirmed in all respect."

Place: Ujjain

Date: August 11, 2025

Registered Office:

75/2 & 3, Industrial Area,

Maksi Road,

Ujjain- 456010

CIN: L33112MP1985PLC003039

E-mail: raajmedisafe@gmail.com

**By order of Board
FOR RAAJ MEDISAFE INDIA LIMITED**

**Sd/-
ARPIT BANGUR
Managing Director
DIN: 02600716**

NOTES:

1. Pursuant to the General Circular No. 09/2024 dated 19 September 2024, issued by the Ministry of Corporate Affairs (MCA) and Circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated 03 October 2024 issued by SEBI (hereinafter collectively referred to as "the Circulars"), companies are allowed to hold AGM through VC, without the physical presence of members at a common venue. Hence, in compliance with the Circulars, the AGM of the Company is being held through VC.
2. A member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his / her behalf and the proxy need not be a member of the Company. Since the AGM is being held in accordance with the Circulars through VC/OAVM, the facility for the appointment of proxies by the members will not be available.
3. Participation of members through VC will be reckoned for the purpose of quorum for the AGM as per Section 103 of the Act.
4. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC. Corporate members intending to authorize their representatives to participate and vote at the meeting are requested to send a certified copy of the Board resolution / authorization letter to the Scrutinizer by email to **mmaheshwarics@gmail.com**.
5. The Register of Members, Beneficial Owners and Share Transfer Books of the Company will remain close from Friday, September 19, 2025 to Thursday, September 25, 2025 (both days inclusive).
6. Explanatory Statement pursuant to section 102 (1) of the Companies Act, 2013 to items No. 4 to 6 is annexed.
7. The Register of directors and key managerial personnel and their shareholding, maintained under Section 170 of the Act, and the Register of Contracts or Arrangements in which the directors are interested, maintained under Section 189 of the Act, will be available electronically for inspection by the members during the AGM. All documents referred to in the Notice will also be available for electronic inspection without any fee by the members from the date of circulation of this Notice up to the date of AGM, i.e. Thursday, September 25, 2025. Members seeking to inspect such documents can send an email to **raajmedisafe@gmail.com**. Relevant documents referred to in the accompanying Notice are open for inspection by the Members at the Company's Registered Office 75/2 & 3, Industrial Area, Maksi Road, Ujjain-456010 on all working days (except Sundays and Public Holidays) between 11.00 a.m. to 2.00 p.m. up to the date of ensuing Annual General Meeting ("AGM") and also at the AGM.
8. Members whose shareholding is in electronic mode are requested to notify any change in postal address, **email id** or bank account details to their respective depository participant(s) (DP)
9. Members are requested to address all correspondence to Ankit Consultancy Pvt Ltd., 60, Electronic Complex, Pardeshipura, Indore-452010, email id: **investor@ankitonline.com**
10. In compliance with Section 108 of the Act, read with the corresponding rules, Regulation 44 of the LODR Regulations and in terms of SEBI circular no. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated December 9, 2020, the Company has provided a facility to its members to exercise their votes electronically through the electronic voting (e-voting) facility to be provided by the **Central Depository Services (India) Limited**. Members who cast their votes by remote e-voting prior to the AGM may participate in the AGM but shall not be entitled to cast their votes again. The manner of voting remotely by members holding shares in dematerialized mode, physical mode and for members who have not registered their email addresses is provided in the 'Instructions for e-voting' section which forms part of this Notice. The Board has appointed M. Maheshwari & Associates, Practicing Company Secretaries, as Scrutinizers to scrutinize the e-voting in a fair and transparent manner.
11. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first serve basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and

Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first serve basis.

12. Members holding shares either in physical or dematerialized form, as on cut-off date, i.e. as on September 18, 2025, may cast their votes electronically. The e-voting period commences on Monday, September 22, 2025 (9:00 a.m. IST) and ends on Wednesday, September 24, 2025 (5:00 p.m. IST). The e-voting module will be disabled by CDSL thereafter. A member will not be allowed to vote again on any resolution on which vote has already been casted. The voting rights of members shall be proportionate to their share of the paid-up equity share capital of the Company as on the cut-off date, i.e. as on September 18, 2025. A person who is not a member as on the cut-off date is requested to treat this Notice for information purpose only.
13. The facility for voting during the AGM will also be made available. Members present in the AGM through VC and who have not cast their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through the e-voting system during the AGM.
14. Any person holding shares in physical form, and non-individual shareholders who acquire shares of the Company and become members of the Company after the Notice is sent and holding shares as of the cut-off date, i.e. September 18, 2025, may obtain the login ID and password by sending a request at helpdesk.evoting@cdslindia.com. However, if he / she is already registered with CDSL for remote e-voting, then he / she can use his / her existing user ID and password for casting the vote. In case of individual shareholders holding securities in demat mode, who acquire shares of the Company and become members of the Company after the Notice is sent and holding shares as of the cut-off date i.e. September 18, 2025 may follow steps mentioned in the Notice under 'Instructions for e-voting.'
15. In compliance with the Circulars, the Annual Report 2024-25 the Notice of the 40th AGM, and instructions for e-voting are being sent through electronic mode to those members whose email addresses are registered with the Company / depository participant(s).
16. We urge members to support our commitment to environmental protection by choosing to receive the Company's communication through email. Members holding shares in demat mode, who have not registered their email addresses are requested to register their email addresses with their respective DP, and members holding shares in physical mode are requested to update their email addresses with the Company's RTA, Ankit Consultancy Pvt Ltd. at investor@ankitonline.com/ operation@ankitonline.com to receive copies of the Annual Report 2024-25 in electronic mode.
17. Members may also note that the Notice of the 40th AGM and the Annual Report 2024-25 is also be available on the Company's website, **www.raajmedisafeindia.com**, websites of the stock exchange, BSE, at www.bseindia.com, respectively, and on the website of CDSL.
18. The Scrutinizer will submit his report to the Chairman of the Company ("the Chairman") or to any other person authorized by the Chairman after the completion of the scrutiny of the e-voting (votes cast during the AGM and votes cast through remote e-voting), not later than 48 hours from the conclusion of the AGM. The result declared along with the Scrutinizer's report shall be communicated to the Stock Exchange BSE Ltd and will also be displayed on the Company's website, **www.raajmedisafeindia.com**.
19. Since the AGM will be held through VC/OAVM in accordance with the Circulars, the route map, proxy form and attendance slip are not attached to this Notice.
20. Members are requested to intimate changes, if any pertaining to their name, postal address, e-mail address, telephone/mobile numbers, Permanent Account Number ('PAN'), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc; -

For Shares held in electronic form: to their Depository Participant only and not to the Company's RTA. Changes

intimated to the Depository Participant will then be automatically reflected in the Company's records which will held the Company and its RTA provide efficient and better service to the Members.

For Shares held in physical form: to the Company's RTA in prescribed Form ISR-1 and other forms as per instructions mentioned in the form. The said form can be downloaded from the Investor Relation Section available on the Company's website.

21. SEBI vide its various circulars and master circular dated May 7, 2024 for Registrars to an Issue and Share Transfer Agents it is mandated for the holders of shares in physical mode to make their folios KYC compliant by submitting Form ISR-1, ISR-2, ISR-4 and nomination Form No. SH-13. The Forms are available on Company's website www.raajmedisafeindia.com>investor relation>shareholder service request Forms.

Place: Ujjain

Date: August 11, 2025

Registered Office:

75/2 & 3, Industrial Area,

Maksi Road,

Ujjain- 456010

CIN: L33112MP1985PLC003039

E-mail: raajmedisafe@gmail.com

**By order of Board
FOR RAAJ MEDISAFE INDIA LIMITED**

**Sd/-
ARPIT BANGUR
Managing Director
DIN: 02600716**

EXPLANATORY STATEMENT

(Pursuant to Section 102 of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

The following statement sets out all material facts relating to the Special Business mentioned in the accompanying Notice:

Item No. 4

SEBI vide Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 dated 12th December 2024, amended Regulation 24A of SEBI (LODR) Regulations, 2015. The amendment mandates Listed Companies to appoint Secretarial Auditor, if Individual for not more than one terms of five consecutive years and if Firm for not more than two terms of five consecutive years, subject to approval of Shareholders.

In compliance with the aforesaid provision and Section 204 of the Companies Act, 2013, the Board of Directors, on the recommendations of the Audit Committee, at their meeting held on August 11, 2025 approved the appointment of Mr. Manish Maheshwari (CP No 3860) of M/s. M. Maheshwari & Associates, Practicing Company Secretaries, as Secretarial Auditor of the Company to hold office from Financial Year 2025-26 till 2029-30, subject to approval of Shareholders.

Pursuant to Regulation 24A of SEBI (LODR) Regulations, 2015, the approval of the shareholder is sought for appointment of M/s. M. Maheshwari & Associates as Secretarial Auditor of the Company to hold office from Financial Year 2025-26 till 2029-30 at such remuneration as may be decided by the Board.

It is pertinent to mention that in terms of Regulation 24A of SEBI (LODR), 2015, the Secretarial Auditor holds a valid Peer Review Certificate issued by the ICSI, has not incurred any of the disqualification as specified by the board and has provided their consent for the appointment.

The documents related to appointment of M/s. M. Maheshwari & Associates, Practicing Company Secretaries, are available for inspection at the Registered Office of the Company. These documents are also accessible on the Company's website.

None of the Directors, Key Managerial Personnel of the Company or their relatives are concerned or interested, financially or otherwise in the resolution no. 4 set out in this Notice.

The Disclosure under Regulation 36 (5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is given hereunder:

Proposed Audit fees payable to the Secretarial Auditors Remuneration	Shall be decided by the Board of Directors of the Company.
Terms of Appointment	First Term of 5 (five) years from Financial Year 2025-26 till 2029-30
Material change in the fee payable to such auditor from that paid to the outgoing auditor along with the rationale for such change	NA
Basis of recommendation and Auditor's credentials	<p>The proposal for proposed appointment of M/s. M. Maheshwari & Associates was considered and approved by Audit Committee on the basis that :-</p> <ol style="list-style-type: none"> 1. The firm has a long association with the company 2. The firm is in Secretarial Practice since last 26 years 3. The firm is well exposed to the secretarial practices followed by listed companies 4. The Secretarial Auditor holds a valid certificate No. 1191/2021 of Peer Review as prescribed by the ICSI.

The Board commends the Resolution for approval of the members as **Special Resolution**.

Item No. 5

Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), inter alia, states that all Material Related Party Transactions ('RPTs') shall require prior approval of the Members by means of an Ordinary Resolution, even if such transaction(s) are in the ordinary course of business and at an arm's length pricing basis. A transaction with a Related Party shall be considered material, if the transaction(s) to be entered into individually or taken together with previous transactions during a financial year, exceeds ₹1,000 crore or 10% of the annual consolidated turnover of a listed entity as per the last audited financial statements of the listed entity, whichever is lower.

In view of the above, Resolution No. 5 is placed for approval by the Members of the Company.

The Management has provided the Audit Committee with relevant details of the proposed RPTs, including material terms and basis of pricing. The Audit Committee, after reviewing all necessary information, has granted its approval for entering into the below mentioned RPTs, subject to approval by the Members at the ensuing Annual General Meeting. The Audit Committee has noted that the said transaction(s) will be at an arm's length pricing basis and will be in the ordinary course of business of the Company.

Details of the proposed RPTs of the Company with Shriji Polymers (India) Limited ('Shriji'), including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, are as follows:

S.No.	Description	Details of Proposed RPTs of the Company with Shriji
1.	Summary of information provided by the Management to the Audit Committee for approval of the proposed RPTs	
a.	Name of the Related Party and its relationship with the Company	Shriji Polymers (India) Limited. Promoters of the Company are the Promoters of Shriji
2.	Name of the Director or Key Managerial Personnel who is related and nature of relationship	Shri Arpit Bangur himself and his relatives are the Promoters and Shareholder of Shriji.
3.	Nature, material terms and particulars of contract or arrangement	<p><u>Nature of Contract or Arrangement</u> Sale of Plastic Liners and Purchase of Raw Materials.</p> <p><u>Duration of Contract or arrangement</u> Arrangement is repetitive in nature and approval is sought for the financial year 2025 -26 and the said approval is valid till next AGM but not exceeding a period of 15 months.</p> <p><u>Pricing</u> The pricing mechanism would be as per Arm's Length criteria based on the market price or alternative pricing method of relevant materials. Valuation report or other external report, as may be applicable, shall be obtained by the parties concerned.</p>
4.	Value of transactions	Value of arrangement shall not exceed 1400 Lakhs
5.	% of the listed entity's annual consolidated turnover for the immediately preceding financial year.	22.43%
6.	Justification for the transaction	The Board is of the opinion that the proposal is in the interest of the Company as it will contribute to the growth of the sales and profit of the Company.

7.	Details of proposed RPTs relating to any loans, inter-corporate deposits, advances or investments made or given by the Company or its subsidiary:	Not Applicable
8.	A copy of the valuation or other external party report, if any, such report has been relied upon	Not Applicable
9.	Any other information relevant or important for the meeting to take decision on the proposed transaction.	All relevant information are mentioned in the Explanatory Statement setting out material facts, pursuant to Section 102(1) of the Act, forming part of this Notice.

Except as above, none of the Directors, their relatives and KMPs are deemed to be concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the notice convening this AGM.

Based on the approval of the Audit Committee, the Board recommends the Ordinary Resolution set forth at Item No.5 of the Notice convening this AGM, for approval by the Members.

The Members may note that in terms of the provisions of the SEBI Listing Regulations, no Related Party shall vote on the Ordinary Resolution set forth at Item No.5 of the Notice, whether the entity is a Related Party to the particular transaction(s) or not.

Item No.6

Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), inter alia, states that all Material Related Party Transactions ('RPTs') shall require prior approval of the Members by means of an Ordinary Resolution, even if such transaction(s) are in the ordinary course of business and at an arm's length pricing basis. A transaction with a Related Party shall be considered material, if the transaction(s) to be entered into individually or taken together with previous transactions during a financial year, exceeds ₹1,000 crore or 10% of the annual consolidated turnover of a listed entity as per the last audited financial statements of the listed entity, whichever is lower.

In view of the above, Resolution Nos. 6 is placed for approval by the Members of the Company.

The Management has provided the Audit Committee with relevant details of the proposed RPTs, including material terms and basis of pricing. The Audit Committee, after reviewing all necessary information, has granted its approval for entering into the below mentioned RPTs, subject to approval by the Members at the ensuing Annual General Meeting. The Audit Committee has noted that the said transaction(s) will be at an arm's length pricing basis and will be in the ordinary course of business of the Company.

Details of the proposed RPTs of the Company with Shriniwas Polyfabrics and Packwell Private Limited ('Polyfab'), including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, are as follows:

S.No.	Description	Details of Proposed RPTs of the Company with Polyfab
Summary of information provided by the Management to the Audit Committee for approval of the proposed RPTs		
1.	Name of the Related Party and its relationship with the Company	Shriniwas Polyfabrics and Packwell Private Limited. (Polyfab) Promoters of the Company are the Promoters of Polyfab
2.	Name of the Director or Key Managerial Personnel who is related and nature of relationship	Shri Arpit Bangur himself and his relatives are the Promoters and Shareholder of Polyfab.
3.	Nature, material terms and particulars of contract or arrangement	<u>Nature of Contract or Arrangement</u>

		<p>Sale of Extruded Polyfilm, Hygiene Products Like Napkin, Job work</p> <p><u>Duration of Contract or arrangement</u></p> <p>Arrangement is repetitive in nature and approval is sought for the financial year 2025-26 and the said approval is valid till next AGM but not exceeding a period of 15 months.</p> <p><u>Pricing</u></p> <p>The pricing mechanism would be as per Arm's Length criteria based on the market price or alternative pricing method of relevant materials. Valuation report or other external report, as may be applicable, shall be obtained by the parties concerned.</p>
4.	Value of transactions	Value of arrangement shall not exceed 1600 Lakhs
5.	% of the listed entity's annual consolidated turnover for the immediately preceding financial year.	25.63%
6.	Justification for the transaction	The Board is of the opinion that the proposal is in the interest of the Company as it will contribute to the growth of the sales and profit of the Company.
7.	Details of proposed RPTs relating to any loans, inter-corporate deposits, advances or investments made or given by the Company or its subsidiary:	Not Applicable
8.	A copy of the valuation or other external party report, if any, such report has been relied upon	Not Applicable
9.	Any other information relevant or important for the meeting to take decision on the proposed transaction.	All relevant information are mentioned in the Explanatory Statement setting out material facts, pursuant to Section 102(1) of the Act, forming part of this Notice.

Except as above, none of the Directors, their relatives and KMPs are deemed to be concerned or interested, financially or otherwise, in the resolution set out at Item No. 6 of the notice convening this AGM.

Based on the approval of the Audit Committee, the Board recommends the Ordinary Resolution set forth at Item No.6 of the Notice convening this AGM, for approval by the Members.

The Members may note that in terms of the provisions of the SEBI Listing Regulations, no Related Party shall vote on the Ordinary Resolution set forth at Item No. 6 of the Notice, whether the entity is a Related Party to the particular transaction(s) or not.

Disclosure relating to a Director seeking appointment/re-appointment pursuant to the provisions of the Act and Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and applicable Secretarial Standards:

Name of Director	Shri Navin Jhawar
DIN :	08729821
Date of Birth	15.09.1981
Date of First appointment	18.08.2021
Qualification	Master of Management Science
Expertise in specific area	Administration and Production Planning and Business Management

Directorships held in other public companies (excluding foreign companies and Section 8 companies)	Nil
Memberships/ Chairmanships of Committees of other public companies (includes only Audit Committee and Stakeholders' Relationship Committee)	Nil
Relationship between Directors, Manager and other Key Managerial Personnel inter-se	Nil
Shareholding of the Company	Nil
Attendance at Board meetings in FY 2024-25	Present in Eleven Board Meeting held during the year 2024-25

Place: Ujjain**Date: August 11, 2025****Registered Office:**

75/2 & 3, Industrial Area,

Maksi Road,

Ujjain- 456010**CIN: L33112MP1985PLC003039**E-mail: raajmedisafe@gmail.com**By order of Board
FOR RAAJ MEDISAFE INDIA LIMITED****Sd/-
ARPIT BANGUR
Managing Director
DIN: 02600716**

THE INSTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- (i) The voting period begins on September 22, 2025 at 9.00 A.M. and ends on September 24, 2025 at 5.00 P.M. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of September 18, 2025 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/websites of Depositories/Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- iv In terms of SEBI circular no. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	<ol style="list-style-type: none"> 1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the

	<p>meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.</p> <p>3) If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option.</p> <p>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
Individual Shareholders holding securities in demat mode with NSDL Depository	<p>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at: https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting</p> <p>4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>
Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- v. Login method for e-Voting and joining virtual meetings for **Physical shareholders and shareholders other than individual holding in Demat form.**
- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
 - 2) Click on "Shareholders" module.
 - 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
 - 4) Next enter the Image Verification as displayed and Click on Login.
 - 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
 - 6) If you are a first-time user follow the steps given below:

	For Physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

- vi After entering these details appropriately, click on "SUBMIT" tab.
- vii. Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- viii. For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions

contained in this Notice.

- ix. Click on the EVSN for the relevant Raaj Medisafe India Limited on which you choose to vote.
- x. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- xi. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- xii. After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- xiii. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- xiv. You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- xv. If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- xvi. There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.

Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
- It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; mmaheshwarics@gmail.com and raajmedisafe@gmail.com (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.

3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops/IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at raajmedisafe@gmail.com. These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to **Company/RTA email id**.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective **Depository Participant (DP)**
3. **For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.**

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

DIRECTORS' REPORT

To ,
The Members of
Raaj Medisafe India Ltd.

Your Directors are pleased to present the 40th Annual Report along with the Company's Audited Financial Statement for the financial year ended March 31, 2025

1. FINANCIAL RESULTS

The Board's Report is prepared based on the financial statements of the Company. The Company's financial performance for the year under review along with previous year's figures are given hereunder:

(Rs. In Thousands)

Particulars	2024-25	2023-24
Sales & Other Income	626194.41	433090.28
Total Expenditure	573646.25	390200.58
Earning before Finance Cost, Depreciation & Tax	88313.77	66916.54
Less: Finance Cost	21280.74	15656.18
Depreciation & Amortization Expenses	14484.87	8370.66
Profit/ (loss) before Tax and extraordinary items	52548.15	42889.70
Exceptional & Extraordinary items	0.00	0.00
Profit / (Loss) before Tax	52837.03	42889.70
Current and prior period Tax	9482.01	6701.84
Deferred Tax	-18246.3	2902.54
Other Comprehensive Income	-625.39	167.64
Profit/ (Loss) for the Year	61312.44	33285.32
Total Comprehensive Income for the year	60687.05	33452.96
Basic & Diluted Earnings (in Rs.) Per Equity Shares of Face Value of Rs. 10/- each.	4.60	3.07

RESULTS OF OPERATIONS

The Highlights of the Company's performance for the year ended March 31, 2025 are as under:

During the financial year ended on March 31, 2025 the Company achieved turnover of Rs. 624204.43 Thousands as against turnover of Rs. 432488.09 Thousands only during the previous year, which is an increase in turnover by 44.33 %.

The Profit before Depreciation & Tax (PBT) for the financial year ended on March 31, 2025 is Rs. 67033.03 Thousand against Rs. 51260.36 Thousand in the previous year.

Earnings per Share as on March 31, 2025 are Rs. 4.60 vis a vis against Rs. 3.07 as on March 31, 2024.

The net worth of the Company stands at Rs. 269154.22 Thousands as at March 31, 2025 as compared to Rs 108367.17 Thousands as at March 31, 2024.

Your Directors are to report that the amount of Rs. 1001.00 Lakhs raised by issue of Fully paid up equity shares has been applied to Company's expansion and Diversification plans during 2024-25

2. CHANGE IN THE NATURE OF BUSINESS:

There was no change in the nature of the business of your Company during the financial year.

3. DIVIDEND

To further strengthen the financial position of the Company and to conserve resources, the Directors have decided not to recommend dividend for the financial year ended March 31, 2025.

4. EQUITY SHARES CAPITAL OF THE COMPANY

There has been no change in the Authorised Capital. The Company has issued and allotted equity shares of Rs. 10 each at premium of Rs. 34 per shares during the year under review. The details of authorized subscribed and paid up capital as at March 31, 2025 are as under:

Particulars	No. of equity shares	Equity Capital (Rs.)
Authorised Capital	1,50,00,000	15,00,00,000
Subscribed Capital		
Capital as on 31.03.2024	1,09,37,612	10,93,76,120
Add: Equity Shares allotted on 06.05.2024	22,75,000	2,27,50,000
Equity Capital as on 31.03.2025	1,32,12,612	13,21,26,120
Less: Partly paid up equity Shares	68,000	3,40,000
Paid-up Equity Capital as on 31.03.2025	1,31,44,612	13,17,86,120

During the year under review:

- The Company has neither issued any shares with differential voting rights nor has granted any stock options or sweat equity;
- The Directors do not hold any instruments convertible into equity capital; and
- The Company has not made any provision of money for purchase of its own shares by employees or by trustees for the benefit of employees.

5. BUSINESS REVIEW

Your Directors are pleased to inform that the Plant & Machinery acquired last year have been brought to in production and these are running satisfactorily. By coming into operations of the said facilities, the Company has commenced the production of Sanitary Napkins.

6. MATERIAL CHANGES, COMMITMENTS AND CHANGE IN THE NATURE OF BUSINESS

There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year and the date of this report.

7. TRANSFER TO RESERVES:

The Company has not transferred any amount to General Reserves and retained the amount available for appropriation in the Profit and Loss Account.

8. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The Management Discussion and Analysis forms an integral part of this Report, as stipulated under Regulation 34(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered with the Stock Exchange, is set out in the Annexure forming part of Annual Report marked as **Annexure – “A”**.

9. CORPORATE GOVERNANCE

Corporate Governance is an ethically driven business process that is committed to values aimed at enhancing an organization's brand and reputation. The Companies Act, 2013 as amended to date and amended Listing Regulations have strengthened the governance regime in the country. The Company is in compliance with the governance requirements provided under the law. The Company is committed to maintain the highest standards of corporate governance and adhere to the corporate governance requirements set out by SEBI. Report on Corporate Governance forming part of the Annual Report marked as **Annexure – “B”**.

A separate report on Corporate Governance is provided together with a Certificate from the Practicing Company Secretary confirming compliance with conditions of Corporate Governance as stipulated under Regulation 34 read with Schedule V of the Listing Regulations, is annexed to the Annual Report.

A Certificate of the Managing Director and Chief Financial Officer of the Company in terms of Regulation 17(8) read with Part B of Schedule II of the Listing Regulations, inter alia, confirming the correctness of the financial statements and cash flow statements, stating that members of Board of Directors and Senior Management have affirmed compliance with the Company's Code of Conduct and adequacy of the internal control measures and reporting of matters to the Audit Committee.

10. INFORMATION PURSUANT TO SECTION 134 OF THE COMPANIES ACT, 2013

- a) **CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES-** During the financial year 2024-25, the Company entered into transactions with related parties as defined under Section 2 (76) of the Companies Act, 2013 read with Companies (Specification of Definitions Details) Rules, 2014, all of which were in the ordinary course of business and on arm's length basis and also in accordance with the provisions of the Companies Act, 2013 read with the Rules issued there under and the Listing Regulations. Further, there were no transactions with related parties which qualify as material transactions under the Listing Regulations. All transactions with related parties were approved by the Audit Committee and are in accordance with the Policy on Related Party Transactions formulated and published on the website of the Company www.raajmedisafeindia.com

The policy is in accordance with the provisions of Companies Act, 2013 read with the Rules issued there under and the Listing Regulations. Prior omnibus approvals are granted by the Audit Committee for related party transactions which are of repetitive nature, entered in the ordinary course of business and on arm's length basis in accordance with the provisions of Companies Act, 2013 read with the Rules issued there under and the Listing Regulations. The details of the related party transactions as per Indian Accounting Standards (Ind AS) - 24 are set out in Note 34 to the Standalone Financial Statements of the Company.

The Form AOC - 2 pursuant to Section 134 (3) (h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014 is set out in the **Annexure - C** to this report.

- b) **EXTRACT OF THE ANNUAL RETURN-** Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return as on March 31, 2025 will be made available on the Company's website on www.raajmedisafeindia.com.
- c) **BOARD MEETINGS** - The details of the number of Board and Committee meetings of the Company are set out in the Corporate Governance Report which forms part of this Report.
- d) **DISCLOSURE BY INDEPENDENT DIRECTORS** - Your Company has received annual declarations from all the Independent Directors of the Company confirming that they meet with the criteria of Independence provided in Section 149(6) of the Companies Act, 2013 and Regulations 16(1) (b) & 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and there has been no change in the circumstances which may affect their status as Independent Director during the year.

The Independent Directors met on February 11, 2025 without the attendance of Non-Independent Directors and members of the Management. The Independent Directors reviewed the performance of Non-Independent Directors and the Board as a whole; the performance of the Chairman of the Company, taking into account the views of Executive Directors and Non-Executive Directors and assessed the quality, quantity and timeliness of flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

- e) **POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION AND OTHER DETAILS-** The Remuneration Policy of the Company is designed to attract, motivate and retain manpower in a competitive and international market. The policy reflects the Company's objectives for good corporate governance as well as sustained long-term value creation for shareholders. The Remuneration Policy applies to the Company's senior management, including its Key Managerial Person and Board of Directors. The Nomination and Remuneration Policy for the members of Board and Executive Management is available on the Company's website www.raajmedisafeindia.com.

- f) **QUALIFICATIONS, RESERVATIONS, ADVERSE REMARKS OR DISCLAIMERS BY THE AUDITORS** - The Notes on financial statement referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation, adverse remark or disclaimer.
- g) **PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED**- Pursuant to Section 134(3)(g) of the Companies Act, 2013 particulars of loans, guarantees or investments provided by the Company under Section 186 of the Act as at end of the Financial Year 2024-25 are disclosed in the Notes to the Financial Statement attached with the Board Report.
- h) **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO** - Details of conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under Section 134 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 is forming part of this report as **Annexure – D**.
- i) **RISK MANAGEMENT**- In line with the regulatory requirements of Section 134(3) of Companies Act, 2013, the Company has framed a Risk Management Policy to identify and access the key business risk areas and to resolve the same risk for smooth operations. A detailed exercise is being carried out at regular intervals to identify, evaluate, manage and monitor all business risks. The Board periodically reviews the risks and suggests steps to be taken to control and mitigate the same through a properly defined framework.
- j) **CORPORATE SOCIAL RESPONSIBILITY**- The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility.
- k) **COMMITTEES** - In terms of the prevailing provisions of the Companies Act, 2013 rules made thereunder and regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended to-date, the Board of Directors of the Company has constituted the following Committees:

Name of the Committee	Provisions of the Companies Act / Regulations of SEBI (LODR)	
	Companies Act	LODR
Audit Committee	Section 177	18
Nomination and Remuneration Committee	Section 178	19
Stakeholder Relationship Committee	Section 178 (5)	20

- l. **FIXED DEPOSIT** - During the financial year 2024-25, your Company has not accepted any deposits within the meaning of Sections 73 and 74 of the Companies Act, 2013 read together with the Companies (Acceptance of Deposits) Rules, 2014.
- m. **SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS, TRIBUNALS** - No significant and material orders have been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.
- n. **PARTICULARS OF EMPLOYEES** - In terms of the provisions of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement showing the remuneration of Managerial personnel is set out in Annexure - E which forms part of this report.
- o. Pursuant to section 143 (12) of the Companies Act, 2013, the auditors have not reported any fraud committed by the Company during the year under review.

11. COMPLIANCE OF SECRETARIAL STANDARD

The Company has complied with the Secretarial Standards issued by the Institute of Company Secretaries of India and approved by the Central Government as required under Section 118 (10) of the Companies Act, 2013.

12. DIRECTORS RESPONSIBILITY STATEMENT**Your Directors state that:**

- a) in the preparation of the annual accounts for the year ended March 31, 2025, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2025 and of the profit of the Company for the year ended on that date;
- c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) the Directors have prepared the annual accounts on a 'going concern' basis;
- e) the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.; and
- f) The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

13. DIRECTORS

The Board of Directors in its meeting held on August 14, 2024 has elevated Shri Arpit Bangur and designated him as Managing Director of the Company. The appointment of Shri Arpit Bangur as aforesaid has been approved by the Members in the Annual General Meeting held on September 25, 2024.

Shri Navin Jhawar was re-designated as Whole-time Director wef August 14, 2024.

The Board of Directors in its meeting held on August 14, 2024 has appointed Shri Hemant Kasliwal and Shri Ateet Agrawal as additional Directors (Designated as Independent Directors). They have been appointed Independent Directors for Five years by the Members in the Annual General Meeting held on September 25, 2024.

Shri Rajesh Kumar Gupta and Shri Vijendra Kumar Sood, Independent Directors of the Company shall be completing their second term on September 24, 2024, therefore, their respective offices were vacated on wef September 25, 2024.

Smt. Krishna Jajoo (DIN:02590793) retires by rotation at ensuing Annual General Meeting and being eligible, offers herself for reappointment`.

The Board Recommends re-appointment of the aforesaid Director in the ensuing Annual General Meeting.

Brief resume of Directors seeking appointment and re-appointment as stipulated under Regulation 36(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been provided as Annexure to the Notice of AGM of the Company.

14. KEY MANAGERIAL PERSONNEL

The Key Managerial Personnel (KMP) in the Company as per Section 203 of the Companies Act, 2013 are as follows:

Mr. Arpit Bangur (DIN:02600716)	:	Managing Director wef from 14.08.2024
Mr. Navin Jhawar (DIN: 08729821)	:	Joint Managing Director
Mr. Sachin Sarda	:	Company Secretary (PAN:AXWPS3668P)

Mrs. Ankita Jain (PAN: ALJPJ7535K) has resigned from the Services of the Company with effect from the close of business hours on May 31, 2025. Therefore, the office of Chief Financial Officer stands vacates with effect from June 1, 2025.

15. EVALUATION OF BOARD, COMMITTEES AND INDIVIDUAL DIRECTORS

Definition of 'Independence' of Directors is derived from Regulation 16 of the SEBI Listing Regulations and Section 149(6) of the Companies Act, 2013. The Company has received necessary declarations under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI Listing Regulations, from the Independent Directors stating that they meet the prescribed criteria for independence.

All Independent Directors have affirmed compliance to the code of conduct for Independent Directors as prescribed in Schedule IV to the Companies Act, 2013. List of key skills, expertise and core competencies of the Board forms part of this Annual Report.

Based on the declarations received from the Independent Directors, your Board of Directors confirm the independence, integrity, expertise and experience (including the proficiency) of the Independent Directors of the Company.

As per regulatory requirements, all the Independent Directors have registered their names in the Independent Director's Databank, pursuant to provisions of the Companies Act, 2013 and rules made thereunder.

The Company has devised a Policy for performance evaluation of Independent and other Directors, Board as a whole and committees thereof which include criteria for performance evaluation of the executive and non-executive directors.

In accordance with the provisions of Schedule IV of the Companies Act 2013, a separate meeting of the Independent Directors was held on February 11, 2025 without the attendance of Non-Independent Directors and Members of the Management. The Committee has reviewed the performance and effectiveness of the Board in this meeting as a whole for the Financial Year 2024-25.

The Policy for evaluation of performance of the Board of Directors is available on the Company's website www.raajmedisafeindia.com.

16. FAMILIARISATION PROGRAM FOR INDEPENDENT DIRECTORS

All independent directors inducted into the Board attend an orientation program. The details of the training and familiarization program are provided in the corporate governance report.

Further, at the time of the appointment of an independent director, the Company issues a formal letter of appointment outlining his/her role, function, duties and responsibilities.

17a. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE PREVENTION, PROHIBITION AND REDRESSAL ACT, 2013

The Company is committed to provide the healthy environment to all its employees. The Company has in place a Prevention of the Sexual Harassment Policy and an Internal complaints committee as per the requirements of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, The policy aims at educating employees on conduct that constitute sexual harassment, ways and means to prevent occurrence of any such incidence and the mechanism for dealing with such incidents, in the unlikely event of its occurrence. The Company has zero tolerance on Sexual Harassment at workplace. During the year under review, no complaints were received against the sexual harassment at workplace.

17b. DISCLOSURE UNDER THE MATERNITY BENEFIT ACT, 1961

The Company declares that it has duly complied with the provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the statutory benefits prescribed under the Act, including paid maternity leave, continuity of salary and service during the leave period, and post-maternity support such as nursing breaks and flexible return-to-work options, as applicable. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.

18. VIGIL MECHANISM

The Company is committed to highest standards of ethical, moral and legal business conduct. Accordingly, the Board of Directors has formulated a Whistle Blower Policy which is in compliance with the provisions of Section 177 (10) of the Companies Act, 2013. The policy provides for a framework and process whereby concerns can be raised by its

employees against any kind of discrimination, harassment, victimization or any other unfair practice being adopted against them. More details on the vigil mechanism and the Whistle Blower Policy of the Company have been outlined in the Corporate Governance Report which forms part of this report.

19. AUDITORS

First term of office of M/s. V.K. Ladha & Associates, Chartered Accountants, Ujjain (Firm Regn. No. 002301C) as Statutory Auditors of the Company shall be upto the conclusion of ensuing Annual General Meeting. M/s. GDK & Associates, Chartered Accountants, Indore (Firm Regn. No. 2159C) who have accorded their consent to act as Statutory Auditors and from whom the Company has received a certificate under section 141 of the Companies Act, 2013 that they are qualified to be appointed as Statutory Auditors, are proposed to be appointed as Auditors of the Company for a period of Five years from the conclusion of the 40th Annual General Meeting upto the conclusion of 45th Annual General Meeting.

The Board recommends for their appointment in the ensuing Annual General Meeting.

20. SECRETARIAL AUDIT REPORT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s. M. Maheshwari & Associates, Practicing Company Secretaries to conduct the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith to this Report and marked as **Annexure – F**.

21. APPOINTMENT OF SECRETARIAL AUDITORS

Pursuant to regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended to-date, the Board of Director in its meeting held on 11-08-2025 has appointed M/s. M. Maheshwari & Associates (Firm Regn. No. U.C.No.12001MP213000 and Peer review No. 1191/2021), Company Secretaries in whole-time Practice from whom the Company has received their consent and eligibility, as Secretarial Auditors for a period of 5 (Five) Years to conduct the Secretarial Audit of the Company for the Financial Years 2025-26 to 2029-30).

The Board recommends their appointment in the ensuing Annual General Meeting.

22. NON DISQUALIFICATION OF DIRECTORS

In terms of the declarations received from the Directors of the Company under section 164 of the Companies Act, 2013, none of the Directors is disqualified to be appointed/re-appointed.

A certificate issued by M/s. M. Maheshwari & Associates, Practicing Company Secretaries, pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed hereto and marked as **Annexure-G**.

23. INTERNAL FINANCIAL CONTROL

According to Section 134(5) (e) of the Companies Act, 2013 the term Internal Financial Control (IFC) means the policies and procedures adopted by the Company for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information.

The Company has adequate system of internal controls to ensure that all the assets are safeguarded and are productive. Necessary checks and controls are in place to ensure that transactions are properly verified, adequately authorized, correctly recorded and properly reported.

24. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATES COMPANIES

During the year under review, pursuant to the provisions of section 2(6) and 2(87) of the Companies Act, 2013, the Company has no subsidiary, joint venture and associate Company.

25. REPORTING OF FRAUDS

During the year under review, neither the Statutory Auditor nor the Secretarial Auditor has reported to the Audit Committee under Section 143(12) of the Companies Act, 2013, any instances of the fraud committed by/on the Company, its officers and employees, the details of which would need to be mentioned in the Board Report.

26. BOARD EVALUATION

In terms of the provisions of Section 134(3)(p) of the Companies Act, 2013 and Regulation 17(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has carried out an annual performance evaluation of its own performance, individual Directors, Chief Financial Officer, Company Secretary as well as the evaluation of the working of Committees. Performance evaluation of Independent Directors was done by the entire Board, excluding the Independent Directors being evaluated.

The manner in which the evaluation has been carried out has been explained in the Corporate Governance Report. The above criteria are broadly based on the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India on January 5, 2017. In a separate meeting of Independent Directors, Performance of Non-Independent directors, the Board as a whole and Chairman of the Company was evaluated, taking into account the views of executive directors and non-executive directors.

27. PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

No application has been made under the Insolvency and Bankruptcy Code; hence the requirement to disclose the details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status as at the end of the financial year is not applicable.

28. INDUSTRIAL RELATIONS

Relation between the Management and its employees has been cordial. Your Directors place on record their appreciation of the efficient and loyal services rendered by the employees of the Company at all levels.

29. ACKNOWLEDGEMENT & APPRECIATION

The Board of Directors place on record its sincere gratitude and appreciation for all the employees at all levels for their hard work, solidarity, cooperation and dedication during the year. The Board conveys its appreciation for its customers, shareholders, suppliers as well as vendors, bankers, business associates, regulatory and government authorities for their continued support.

For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED

Place: Ujjain

Date: August 11, 2025

Sd/-
NAVIN JHAWAR
JT. MANAGING DIRECTOR
DIN: 08729821

Sd/-
ARPIT BANGUR
MANAGING DIRECTOR
DIN:02600716

MANAGEMENT DISCUSSION AND ANALYSIS REPORT- 2025-26

The Management Discussion and Analysis Report are prepared in adherence to the spirit enunciated in the Code of Corporate Governance, approved by the Securities and Exchange Board of India and in compliance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Market Overview- Plastic packaging industry

The Indian packaging industry, valued at approximately USD 75 billion in FY20, is projected to grow at a CAGR of 18-20% and reach nearly USD 200 billion by FY25. This growth is driven by the retail market, which is the 5th largest sector in India's economy and has shown steady growth with high potential for expansion, particularly in exports.

Packaging plays a crucial role in determining a product's perceived value. However, with the wide variety of packaging and box options available, choosing the most suitable solution can be challenging. Packaging can generally be divided into two main categories: Rigid Packaging and Flexible Packaging. India is one of the world's biggest and fastest growing flexible packaging markets. The growth is expected to be driven by population growth, urbanization, and improved quality of life, increasing environmental awareness and increasing consumerism.

Rigid Plastic Packaging

Rigid plastic, which includes products and packaging made from plastic resin, is predominantly used for molded items such as food containers, tubes, cups, bottles, pots, cans, and closures. This type of packaging is rapidly replacing traditional materials like metal cans, glass bottles, aluminum tubes, and metal caps in various applications. The primary materials used in rigid plastics are PET (Polyethylene terephthalate), PP (Polypropylene), and HDPE (High-Density Polyethylene).

The growth of this category is driven by factors such as demand for lower-cost packaging, technological innovation and development, a shift towards packaged products by middle-class consumers, modern retail formats that emphasize product presentation, and a growing desire for higher-quality products. Rigid packaging offers the best alternative for recyclability and reusability compared to flexible, glass, or metal packaging.

The market for rigid plastic packaging in India has grown significantly in recent years and is expected to continue growing at a CAGR of around 10-12% by FY 25. The Northern region is the largest market for rigid plastic packaging, accounting for 35% of the market share, followed by the West with 32%.

Flexible packaging

Flexible packaging, made of easily moldable materials, is a rapidly growing segment of the packaging industry. It utilizes materials such as paper, plastic film, foil, and metalized or coated papers to preserve product freshness and extend shelf life. Compared to rigid plastic packaging, it is lighter, takes up less space, and is easier to dispose of. The market for flexible packaging is estimated to grow at a CAGR of 15-18% by FY25, with plastics dominating due to their moisture-resistant properties. Flexible packaging has various applications in the food and non-food industries, including ready-to-eat foods, boil-in-bag pouches, insulation, cosmetics, and healthcare. India is one of the world's largest and fastest-growing flexible packaging markets, with growth driven by factors such as population growth, urbanization, improved quality of life, environmental awareness, and consumerism.

We are pleased to inform that, due to our remarkable growth over the last few years, we are expanding!

Looking at the various exciting business opportunity, we at Raaj Medisafe India Limited, have decided to explore huge business potential in Hygiene industry. In hygiene industry, we aim to cater needs of Baby diapers, sanitary pads, Panty liners, Maternity pads.

Hygiene industry**Market Overview:**

The Indian tissue paper and hygiene product market is expected to grow significantly until 2030, driven by increasing income of urban consumers, improving literacy rates, and growing awareness about hygiene. The demand for baby diapers and sanitary napkins is on the rise, making it a promising venture for entrepreneurs.

Madhya Pradesh offers several initiatives that can benefit manufacturers of sanitary napkins and baby diapers. While there aren't specific financial benefits exclusively for baby diaper manufacturers, the state's focus on promoting menstrual hygiene creates opportunities for sanitary napkin producers. Here are some potential benefits:

Government Schemes:

- Sanitation and Hygiene Scheme: Provides ₹300 per year to schoolgirls for buying sanitary napkins, promoting demand for quality products.
- Udita Scheme: Aims to create awareness about menstrual hygiene, increasing demand for sanitary napkins and potentially benefiting local manufacturers.

Industry Opportunities:

The growing awareness of menstrual hygiene in Madhya Pradesh, presents opportunities for local manufacturers to cater to the increasing demand for sanitary napkins. By focusing on quality, innovation, and sustainability, manufacturers can establish themselves in the market and benefit from government initiatives

Sanitary napkins

The Indian sanitary napkin market touched US\$ 618.4 million worth in 2021. Looking at the statistics, reports anticipate the market to touch US\$ 1,185.0 million by 2027, thereby exhibiting a CAGR of 11.31% during 2022-2027. India Sanitary Pads Market has valued at USD 685.89 million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 6.23% through 2029.

Diapers

The diaper market in India size reached US\$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7% during 2024-2032. The rising concerns among parents regarding the overall health and hygiene of their babies, growing prevalence of various health conditions, and increasing consciousness regarding personal hygiene are among the key factors driving the market growth.

Looking ahead, the volume of the Baby Diapers market is expected to reach 1.4bn kg by 2029. Additionally, a volume growth of 4.4% is projected for 2025. On average, each person in India is expected to consume 0.8kg units of Baby Diapers market in 2024.

Internal Control:-

The Company has put into place an Internal Control system to monitor the movement of parameters considered important for the business. The Company has an Internal Audit Department reporting directly to the management. This department is responsible for monitoring of the above parameters with suitable internal control procedures.

Risk and Concern:-

Availability of desired RM at affordable price, growing competition, pricing and margins, Talent management, logistics will be the critical aspects for company as well competitions.

All the similar industries use the same strategy to capture the emerging markets but difference lies in the quality of execution.

The company to stay in market has to lower the cost of production and have to adapt the strategies as per the changing environment and policies to get strategic advantage.

Financial & Operational Performance:-
(Rs. in Thousand)

Particulars	Year ended 31.03.2025	Year ended 31.03.2024	% Changes
Gross Income	626194.41	433090.28	44.58%
Net Profit/(Loss) After Interest, Depreciation & Tax	61312.44	33285.32	84.20%

The Key Financial ratios of the Company are as under:

a.	Debtors Turnover	5.08
b.	Inventory Turnover	5.10
c.	Interest Coverage ratio	3.51
d.	Current Ratio	1.21
e.	Debt Equity Ratio	.66
f.	Operating Profit Margin (%)	.30
g.	Net Profit Margin (%)	9.72

Human Resources:-

Our Company believes in philosophy of communicating with the entire team in a two way process. Company also believes in the principal of proper delegation of authority which results in upliftment of Commitment level, responsibility and accountability of entire team right from Managing Director to Lowest level of administration. Every effort is made to implement the suggestions received and to encourage staff for more suggestion. During the financial year ended on 31st March 2024 the company has maintained cordial and harmonious relation with the employees, negligible attrition at staff and worker level, adherence to compliances, as applicable. Our focus would remain on hiring the right, retain them successfully and remain complied with the laws of land at any given point in time.

Cautionary Statement:-

Actual performance may differ from projections made as the Company's operations are subject to various economic conditions, government regulations and other incidental factors.

For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED

Place: Ujjain
Date: August 11, 2025

Sd/-
NAVIN JHAWAR
JT. MANAGING DIRECTOR
DIN: 08729821

Sd/-
ARPIT BANGUR
MANAGING DIRECTOR
DIN:02600716

**ANNEXURE TO THE DIRECTORS' REPORT
REPORT ON CORPORATE GOVERNANCE**

1. Company's Philosophy

Your Company's Philosophy on code of Corporate Governance is based on attainment of high level of transparency, accountability, and adequate disclosures and economic value addition. All employees are guided by the Company's policies on important issues, including our relationship with consumers, stakeholders and Government.

Your Company has taken care of the governance framework is incorporated with the applicable amendments introduced in the Listing Regulations and the same is proactively communicated and absorbed down the line with a view to strengthen its philosophy of Corporate Governance.

2. Board of Directors

In keeping with the commitment of the Management for the principle of integrity and transparency in business operations for good corporate governance, the Company's policy is to have an appropriate blend of executive, non-executive and independent directors to maintain the independence of the Board, and to separate the board functions of governance and management.

The Board, inter alia, focuses on strategic planning, risk management, compliance, corporate governance to maintain high standards of ethical conduct and integrity and succession planning for the Directors. The composition of the Board is in conformity with Regulation 17 of the Listing Regulations as well as the Companies Act, 2013 read with the Rules issued thereunder.

3. Committee of Directors

The Board has constituted various Committees with an Optimum representation of its members and with specific terms of reference in accordance with the Companies Act, 2013 and the Listing Regulations. The Company currently has 3 (Three) Committees of the Board, namely, Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee.

Composition, Attendance & Information of other Directorship/ Committee Memberships

The Board of Directors comprises of six members (consisting of three independent directors). The composition of Board of Directors and their attendance for the financial year 2024-25 is as under:

Name of Director	Category	No. of Board Meetings attended	Attendance in Last AGM	List of outside Directorship held in Public Limited Companies	Committee Membership	
					Chairman	Member
Shri Arpit Bangur	Chairman & Managing Director Promoter Director	11	Yes	Nil	Nil	Nil
Shri Navin Jhavar	Jt. Managing Director	11	Yes	Nil	Nil	Nil
Smt. Krishna Jajoo	Woman Director	9	No	Nil	Nil	Nil
Shri Rajesh Kumar Gupta *	Independent Director	6	No	Nil	1	2
Shri Vijendra Kumar Sood *	Independent Director	6	No	Nil	1	2
Shri Rakesh Agrawal	Independent Director	11	Yes	Nil	1	2
Shri Hemant Kasliwal **	Independent Director	7	No	Nil	1	2
Shri Ateet Agrawal **	Independent Director	7	Yes	Nil	1	2

*Shri Rajesh Kumar Gupta and Shri Vijendra Kumar Sood, ceased to be Independent Directors wef from 25.09.2024 on completion of Second Term.

** Shri Hemant Kasliwal and Shri Ateet Agrawal have been appointed Independent Directors wef 14.08.2024 and regularized in the 39th Annual General Meeting held on 25.09.2024.

Meetings of the Board

During the financial year 2024-25, the Board of Directors met 11 times on the following dates:

April 8, 2024, May 6, 2024, May 29, 2024, July 1, 2024, August 14, 2024, September 17, 2024, November 12, 2024, January 2, 2025, February 11, 2025, March 1, 2025 and March 29, 2025.

Matrix of Skill/Expertise/ Competencies is of the Board of Directors:

In terms of the requirements of the SEBI Listing Regulations, the Board has identified and approved the list of core Skill/Expertise/ Competencies as required in the context of Company's Business(es) and Sector(s) for it to function effectively. Broadly, the essential skills identified by the Board are categorized as under: -

Strategy and Planning Competencies	Appreciation of long term trends, strategic choices and experience in guiding and leading management teams to make decisions' in uncertain environment.
Administrative Competencies	Management of Time and Priority Setting, Goals and Standard Setting, Work Planning, Monitoring, Scheduling and Controlling.
Marketing Competencies	Experience in developing strategy to grow sales and market share, build brand awareness and equity and enhance enterprise reputation.
Law & Business Competencies	Understanding of the relevant laws, rules, regulation policies applicable to the organization/industry/sector and level/status of compliances thereof and understanding of business ethics, ethical polices, codes and practices of the organization.
Assessing Risks and Decision – Making Competencies	It involves the ability to evaluate alternatives, identify limits, assign weights to each option and choose the best option to achieve the desired goals and standards

These skills/ competencies are broad-based, encompassing several area of expertise/experience. Each Director may possess varied combinations of skills/experience within the described set of parameters and it is not necessary that all Directors possess all skills/experience listed therein. In the table below, the specific areas of focus or expertise of individual board members have been highlighted:

Name of Director	Area of Skills / Expertise / Competencies				
	Strategy and Planning Competencies	Administrative Competencies	Marketing Competencies	Law & Business Competencies	Assessing Risks and Decision – Making Competencies
Shri Arpit Bangur	YES	YES	YES	YES	YES
Shri Navin Jhawar	YES	YES	YES	YES	YES
Smt. Krishna Jajoo	YES	YES	NO	YES	NO
Shri Rakesh Agrawal	YES	YES	NO	YES	YES
Shri Hemant Kasliwal	YES	YES	YES	YES	YES
Shri Ateet Agrawal	YES	YES	YES	YES	YES

4. Audit Committee

The Audit Committee comprises of three Independent Directors. The Audit Committee met on regular intervals during the year under review.

Objective

The objective of the Audit Committee is to monitor and provide effective supervision of the Management's financial reporting processes with a view to ensure accurate and proper disclosure and the transparency and quality of financial reporting. The committee also reviews the financial and risk management policies, and the adequacy of internal control systems of the Company and meets Statutory Auditors periodically.

Terms of Reference

The scope of activities of the Audit Committee is as set out in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 177 of the Companies Act, 2013. These broadly include oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that Company's financial statements are fair and credible, to meet Internal Auditors and Statutory Auditors to discuss their findings/ suggestions, to review weaknesses in internal controls reported by Auditors, to review financial reporting systems and internal control systems, to review quarterly/half yearly/annual financial results and other matters.

Composition, Meetings and Attendance

The meetings of the Audit Committee were held 6 times on April 4, 2024 May 29, 2024, August 14, 2024, November 12, 2024, February 11, 2025 and March 24, 2025. The details of the meetings held and attended are as given below:

Name of Director	Category of Director	No. of Committee Meetings held	Attendance at committee Meeting
Shri Rajesh Kumar Gupta * (Chairman)	Independent Director	3	3
Shri Vijendra Kumar Sood * (Member)	Independent Director	3	3
Shri Rakesh Agrawal (Member)	Independent Director	6	6
Shri Hemant Kasliwal ** (Chairman)	Independent Director	3	3
Shri Ateet Agrawal ** (Member)	Independent Director	3	3

* Shri Rajesh Kumar Gupta and Shri Vijendra Kumar Sood vacated their respective offices on completion of their 2 terms as Independent Directors wef September 25, 2024.

** Shri Hemant Kasliwal and Shri Ateet Agrawal have been appointed as Independent Directors wef August 14, 2024

The representatives of the Statutory Auditors are permanent invitees to the Audit Committee Meetings. The MD, the Chief Financial Officer (CFO), the Internal Auditor attends Audit Committee Meetings. The Company Secretary is the Secretary to the Committee. The Internal Auditor submits his reports directly to the Audit Committee.

5. Nomination and Remuneration Committee

The Nomination and Remuneration Committee has been constituted in accordance with the requirements of statutes and its terms of reference are in compliance with the governing provisions of the Companies Act, 2013 and Regulation 19 of the Listing Regulations.

The terms of reference of the Committee inter alia, include the following:

- formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to the remuneration of the directors, key managerial personnel and other employees;
- formulation of criteria for evaluation of performance of independent directors and the board of directors;
- devising a policy on diversity of board of directors;
- identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal.
- whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.
- recommend to the board, all remuneration, in whatever form, payable to senior management.

S.No.	Name of Director	No. of meetings	
		Held	Attended
1.	Shri Rakesh Agrawal (Chairman)	1	1
2.	Shri Rajesh Kumar Gupta (Member)	1	1
3.	Shri Vijendra Kumar Sood (Member)	1	1

The Committee met once during the year on August 12, 2024.

Remuneration of Managing Director & CEO/ Whole Time Directors:

- At the time of appointment or re-appointment of the Managing Director & CEO/ Whole Time Directors, such remuneration shall be paid as may be mutually agreed between the Company (which includes the Nomination and Remuneration Committee and the Board of Directors) and the Managing Director & CEO/ Whole Time Directors within the overall limits prescribed under the Companies Act, 2013 and Schedule V of the Companies Act, 2013.
- The remuneration to Managing Director/ Whole-time Director shall be subject to the approval of the Members of the Company in General Meeting.

6. Stakeholders Relationship Committee:

S.No.	Name of Director	No. of meetings	
		Held	Attended
1.	Shri Ateet Agrawal (Chairman)**	7	7
2.	Shri Rakesh Agrawal (Member)	10	10
3.	Shri Hemant Kasliwal (Member)**	7	7
4.	Shri Rajesh Kumar Gupta *	3	3
5.	Shri Vijendra Kumar Sood *	3	3

* Shri Rajesh Kumar Gupta and Shri Vijendra Kumar Sood vacated their respective offices on completion of their 2 terms as Independent Directors wef September 25, 2024.

** Shri Hemant Kasliwal and Shri Ateet Agrawal have been appointed as Independent Directors wef August 14, 2024

During the year under review, 12 complaints were received from the Shareholders which were resolved suitably. No complaints were pending as on March 31, 2025. 10 (Ten) Committee Meetings were held on June 18, 2024, July 3, 2024, August 21, 2024, November 4, 2024, November 28, 2024, December 20, 2024, January 6, 2025, January 20, 2025, February 4, 2025 and February 28, 2025.

7. General Body Meetings

i. The details of General Meetings held in last 3 years are as under:

Year	Nature of Meeting	Venue	Date	Time
2024-25	39th AGM	Through Video Conferencing	25.09.2024	3.00 P.M.
2023-24	EGM 27.03.2024	Through Video Conferencing	27.03.2024	4.00 P.M.
2023-24	38th AGM	Through Video Conferencing	27.09.2023	3.00 P.M.
2022-23	37th AGM	Through Video Conferencing	28.09.2022	3.00 P.M.

ii. The details of Special Resolutions passed in the above Annual General Meetings are as follows.

Meeting	Special Resolutions passed in the Annual General Meetings
39th AGM (2024-25)	1. Authority to Board of Directors to create mortgage/ charge on whole or substantially the whole or any one or more of the undertakings of the Company as per Section 180 (1)(a) of the Companies Act, 2013. 2. Authority to Board of Directors to borrow the money in excess of the limits prescribed in Section 180 (1) (c) of the Companies Act, 2013.
EGM 27.03.2024	Further Issue of Equity Shares on Preferential Basis
38th AGM (2023-24)	No

The shareholders passed all the resolutions including all the ordinary and special businesses as set out in the respective notices.

8. Disclosure

i. **Related Party Transaction:** All transactions entered into with Related Parties as defined under the Companies Act, 2013 and Regulation 23 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, during the financial year were in the ordinary course of business and on an arm's length pricing basis and do not attract the provisions of Section 188 of the Companies Act, 2013.

The Company has taken prior shareholders' approval in the annual general meeting held in the year 2021 in connection with material significant related party transactions which may be entered in the next 5 years. During the financial year 2024-25, there were materially significant transactions with related parties for which prior shareholder's approval accorded as stated above. Suitable disclosure as required by the Accounting Standards (AS18) has been made in the notes to the Financial Statements.

The Audit Committee and the Board has approved a policy for related party transactions which has been uploaded on the Company's website.

ii. **Details of Non-Compliance:** The Company has complied with the requirements of the stock exchanges, SEBI and other statutory authorities on all matters related to capital markets during the last three years. There was neither penalty imposed nor any strictures issued on the Company by the Stock Exchanges, SEBI or any other statutory authority relating to the above except penalty imposed by BSE for delay in submission of Listing Application.

iii. **Whistle Blower Policy:** Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 and applicable provisions of section 177 of the Companies Act 2013 requires every listed company shall establish a whistle Blower policy/Vigil Mechanism for the directors and employees to

report genuine concerns or grievances about unethical behavior, actual or suspected fraud or violation of the company's code of conduct for Directors and senior management executives ("the Code") which lays down the principles and standards that one should govern the actions of the Company and its employees. Any actual or potential violation of code, however insignificant or perceived as such, would be a matter of serious concern for the Company. Such a vigil mechanism shall provide for adequate safeguards against victimization of directors and employees who avail of such mechanism and also make provisions for the direct access to the chairperson of Audit Committee in exceptional cases.

- iv. **Compliance of mandatory and non-mandatory requirements:** The Company has implemented all mandatory requirements specified under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.
- v. **Prevention of Insider Trading:** The Company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company. The Code requires pre-clearance for dealing in the Company's shares and prohibits the purchase or sale of Company shares by the Directors and the designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the Trading Window is closed. The Company Secretary & Compliance officer is responsible for implementation of the Code.

All the Directors and the designated employees have confirmed compliance with the Code.

9. **COMMUNICATION WITH THE MEMBERS/ SHAREHOLDERS:** The unaudited quarterly results are announced within forty-five days of the close of the quarter. The audited annual results are announced within two months from the close of the financial year as per the requirements of the SEBI (Listing obligation and Disclosure Requirements) Regulation 2015. The aforesaid financial results are sent to BSE Limited (BSE), where the Company's equity shares are listed, immediately after these are approved by the Board. The results are thereafter given by way of a Press Release to news agencies/ and are published in leading English and Hindi daily newspapers. The audited financial statements form a part of the Annual Report which is sent to the Members well in advance of the Annual General Meeting.

The Annual Report of the Company, the quarterly and the annual results of the Company are also placed on the Company's website: www.raajmedisafeindia.com and can be downloaded.

In compliance with SEBI (Listing obligation and Disclosure Requirements) Regulation 2015, the quarterly results, shareholding pattern, quarterly compliances and all other corporate communication to the BSE Limited, are filed electronically on BSE's on-line portal website www.listing.bseindia.com and are also disseminated on the Company's website <https://www.raajmedisafeindia.com>.

10. General Shareholders Information

1.	Annual General Meeting	
	Date/Day	: 25th September, 2025, Thursday
	Time	: 3.00 PM
	Venue	: Through Video conferencing/OAVM
2.	Financial Year of the Company	1st April, 2024 to 31st March, 2025
3.	Results for the Quarter ending:	
	June 30, 2025	On or before 14th August, 2025
	September 30, 2025	On or before 14th November, 2025
	December 31, 2025	On or before 14th February, 2026
	March 31, 2026	On or before 30th May, 2026 (Audited)
4.	Date of Book closure	Friday, September 19, 2025 to Thursday, September 25, 2025 (both days inclusive).
5.	Listing of Equity Shares on the Stock Exchanges	BSE Limited, Mumbai Listing Fees as applicable has been paid
6.	Stock Code	1. BSE 524502 2. INE548H01015

Investor Services:

The Company has a Registrar and Share Transfer Agent M/s Ankit Consultancy Pvt. Ltd., having their office at 60, Electronic Complex, Pardeshipura, Indore (M.P.) which offers all share related services to its Members and Investors.

These services include transmission/dematerialization of shares, payment of dividends, sub-division/consolidation / renewal/issue Letter(s) of confirmation in lieu of Share Certificates reported lost/misplaced.

The Share Transfer Agent is registered with SEBI as Registrar to an Issue/Share Transfer Agent in Category II Share Transfer Agent and the registration code is INR 000000767.

Address for Correspondence with the Share Transfer Agent of the Company

Ankit Consultancy Private Limited

Plot No. 60, Electronic Complex,

Pardeshipura, Indore (M.P.) 452001,

Phone: 0731-4065797/4065799

Email: investor@ankitonline.com, operation@ankitonline.com

Members who hold shares in dematerialized form should correspond with the Depository Participant with whom they maintain Demat Account/s, for their queries relating to shareholding, change of address. However, queries relating to non-receipt of annual reports and other matters and relating to shares held in physical mode should be sent to the Share Transfer Agent of the Company.

Members are requested to ensure that correspondence for change of address, change in bank details, processing of unclaimed dividend, subdivision of shares, renewals/split/consolidation of share certificates, reporting of loss of share certificates should be signed by the first named Member as per the specimen signature registered with the Company.

Members are requested to indicate their DP ID & Client ID/ Ledger Folio number in their correspondence with the Company/RTA and also to provide their Email addresses and telephone numbers to facilitate prompt response from the Share Transfer Agent of the Company.

Exclusive E-Mail ID

The Company has designated an e-mail ID to enable the Members and Investors to correspond with the Company. The e-mail ID is raajmedisafe@gmail.com.

Stock Market Price Data (In Rs. Per share)

The monthly high / low price of equity shares traded on the Bombay Stock Exchange are as given below:

Month	Bombay Stock Exchange - Share Price (Amount in Rs.)				
	High	Low	Month	High	Low
April 2024	56.76	48.60	October 2024	122.60	91.00
May 2024	76.11	46.20	November 2024	94.00	78.09
June 2024	104.85	71.00	December 2024	95.88	80.80
July 2024	108.81	90.00	January 2025	81.85	64.50
August 2024	106.05	97.00	February 2025	77.09	63.56
September 2024	121.43	93.00	March 2025	81.00	69.60

The monthly high / low BSE Sensex are as given below:

Month	High	Low	Month	High	Low
April 2024	75124.28	71816.46	October 2024	84648.4	79137.98
May 2024	76009.68	71866.01	November 2024	80569.73	76802.73
June 2024	79671.58	70234.43	December 2024	82317.74	77560.79
July 2024	81908.43	78971.79	January 2025	80072.99	75267.59
August 2024	82637.03	78295.86	February 2025	78735.41	73141.27
September 2024	85978.25	80895.05	March 2025	78741.69	72633.54

SHARE TRANSFER SYSTEM AND OTHER RELATED MATTERS
i. Permanent Account Number (PAN)

Members who hold shares in physical form are advised that SEBI has made it mandatory that a copy of the PAN card of the members, surviving joint holders/legal heirs be furnished to the Company/RTA while obtaining the services of transposition, transmission and issue of duplicate share certificates. Necessary request Form can be downloaded from Company's website www.raajmedisafeindia.com>>Investor relation>>Shareholder Service Request Forms- Download

ii. Pending Investors' Grievances

Any Member/ Investor, whose grievance has not been resolved satisfactorily, may kindly write to the Company Secretary at the Registered Office with a copy of the earlier correspondence.

iii. Reconciliation of Share Capital Audit

As required by the Securities & Exchange Board of India (SEBI) quarterly audit of the Company's share capital is being carried out by an independent external Company Secretary in whole-time Practice, with a view to reconcile the total share capital admitted with National Securities Depository Limited (NSDL) and Central Depository Service (India) Limited (CDSL) and held in physical form, with the issued and listed capital. The Reconciliation of Share Capital Audit Certificate issued by the External Company Secretary in regard to the same is submitted to BSE Limited, and is also placed before Stakeholders' Relationship Committee and the Board of Directors.

The Company has entered into agreement with National Securities Depository Limited (NSDL) and Central Depository Service (India) Limited (CDSL) whereby Members have an option to dematerialize their shares.

Distribution of Shareholding as on 31.03.2025

Shareholding of nominal value of Rs.	No. of Shareholders	% of Shareholders	Amount (Rs.)	% of share holding
Up to 1000	3982	48.86	3974370	3.01
1001 – 2000	2234	27.41	4465100	3.38
2001 – 3000	426	5.23	1276800	0.97
3001 – 4000	232	2.85	928000	0.70
4001 – 5000	606	7.43	3029800	2.29
5001 – 10000	405	4.97	3317000	2.51
10001 – 20000	153	1.88	2224800	1.68
20001 – 30000	34	0.41	885000	0.67
30001 – 40000	11	0.13	384000	0.29
40001 – 50000	7	0.09	328000	0.25
50001 – 100000	20	0.25	1480000	1.12
100001 & above	40	0.49	109833250	83.13
Total	8150	100	132126120	100

Shareholding pattern as on 31.03.2025

S. No.	Category	No. of Share held	% of share holding
1	Promoter and Promoter Group	9703625	73.45
2	Private Corporate Bodies, NRI and Other	463300	3.50
3	Indian Public	3045687	23.05
	Total	13212612	100

Other Important Information
(a) Nomination Facility

Shareholders holding shares in physical form and desirous of making a nomination in respect of their shareholding in the Company, as permitted under Section 72 of the Companies Act, 2013, read with the Companies (Share Capital and Debentures) Rules, 2015 are requested to submit to the Company nomination in the prescribed Form SH-13 (available on Company's website www.raajmedisafeindia.com for this purpose).

(b) Updation of Shareholders Information

Shareholders holding shares in physical form are requested to notify the changes to the Company/ its RTA, promptly by a written and duly signed request and Shareholders holding shares in electronic form are requested to send their instructions directly to their Depository Participants (DPs).

(c) SEBI vide its circular No. SEBI/HO/MIRSDfMIRSD-PoD 1/P/CIR/2024/37 dated March 16, 2024 has made it mandatory to the holders of securities in Physical Mode to provide their PAN, Email address, Mobile No., Bank Account Details and Nomination to the Registrar and Share Transfer Agent (RTA) of the Company. The relevant formats for Nomination and Updation of PAN/ KYC details viz; ISR-1, ISR-2, ISR-3, ISR-4, SH-13, SH-14 and SEBI circular are also available on the website of RTA at www.ankitonline.com and company's website: www.raajmedisafeindia.com > Investor Relations > Shareholder Service Request Forms- Download.

In this connection, the Company has sent the communication from time to time to the shareholders holding securities of the Company in physical Form.

Shareholders holding securities of the Company in Physical Form are requested to submit the KYC Forms as aforesaid to the RTA Ankit Consultancy Pvt. Ltd. at the earliest to avoid future complication .

(d) Shareholders are requested to keep record of their specimen Signature before lodgement of shares with the Company to obviate possibility of differences in signature at a later date.

Dematerialization of shares and liquidity: 11335492 (85.79%) were held in dematerialized form and 1877120 shares (14.21%) were in physical form.

Plant Location:

The Company is engaged in the manufacturing of Disposable Hygiene Products, HDPE containers and PP Closures and plastic liners for packing of goods and Aluminum Crown caps.

The Company's Manufacturing Capacities are located at:

- 75/2 & 3, Industrial Area, Maksi Road, Ujjain-456010
- 46, Sector III, Industrial Area, Pithampur – 454774
- 106, Sector III, Industrial Area, Pithampur – 454774

Address for correspondence:

Shareholders may address their communications to:

Name of the Executive	Designation	Address
Mr. Sachin Sarda	Compliance Officer	RAAJ MEDISAFE INDIA LIMITED 75/2 & 3, Industrial Area, Maxi Road, Ujjain-456010 Mail ID: sachin_sarda19@yahoo.co.in , raajmediafe@gmail.com

Other Disclosure:

The Company has maintained all the policies as required by law for better functioning and Corporate Governance and the same are disseminated on the website of the Company i.e. www.raajmedisafeindia.com

Non- compliance of any requirement of Corporate Governance Report of sub-paras (2) to (10) to Schedule V of the Listing Regulations:

The Company has complied with all the requirements in this regard, to the extent applicable.

Disclosure of compliance with Corporate Governance requirements specified in Regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the Listing Regulations:

S. No.	Particulars	Regulation	Compliance Status Yes / No / N.A.
1.	Board of Directors	17	Yes
2.	Maximum Number Directorships	17A	Yes
3.	Audit Committee	18	Yes
4.	Nomination and Remuneration Committee	19	Yes
5.	Stakeholders Relationship Committee	20	Yes
6.	Risk Management Committee	21	N.A.
7.	Vigil Mechanism	22	Yes
8.	Related Party Transaction	23	Yes
9.	Corporate governance requirements with respect to subsidiary of listed entity	24	N.A.
10.	Secretarial Audit and Secretarial Compliance Report	24A	Yes
11.	Obligations with respect to independent directors	25	Yes
12.	Obligations with respect to directors and senior management	26	Yes
13.	Other corporate governance requirements	27	Yes
14.	Website	46(2)(b)to (i)	Yes

**For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED**

Place: Ujjain

Date: August 11, 2025

Sd/-
NAVIN JHAWAR
JT. MANAGING DIRECTOR
DIN: 08729821

Sd/-
ARPIT BANGUR
MANAGING DIRECTOR
DIN:02600716

**Certificate regarding compliance of conditions of Corporate Governance
{Under Regulation 34(3) and Schedule V (E) of the SEBI
(Listing Obligations and Disclosure Requirements) Regulation, 2015}**

To,
The Members,
RAAJ MEDISAFE INDIA LIMITED
CIN: L33112MP1985PLC003039
75/2 and 3, Industrial Area, Maksi Road,
Ujjain MP 456010 IN

We have examined the compliance of Corporate Governance conditions by M/s RAAJ MEDISAFE INDIA LIMITED ("the Company") (CIN L33112MP1985PLC003039) for the year ended March 31, 2025, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The compliance of the conditions of Corporate Governance is the responsibility of the management of the Company. Our responsibility includes the design, implementation and maintenance of internal control and procedures to ensure the compliance with the conditions of the Corporate Governance stipulated in Listing Regulations.

Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in regulations 17 to 27 and clauses (b) to (i) of regulation 46(2) and para C and D of Schedule V of the Listing Regulations during the year ended March 31, 2025.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

This certificate is issued solely for the purpose of complying with the aforesaid Regulations and may not be suitable for any other purpose.

For M. Maheshwari & Associates
Company Secretaries
Firms U.C.N. I2001MP213000

Sd/-
Manish Maheshwari
Proprietor
FCS - 5174
CP-3860
PR NO. 1191/2021

Date : 7th August 2025
Place : Indore
UDIN : F005174G000955541

Declaration Code of Conduct

This is to confirm that the Board of Directors of the Company has laid down a Code of Conduct for its member and senior management personnel of the Company and the same has also been posted on the Company's website. It is further confirmed that all the Director and Senior Management Personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the Financial Year ended 31st March, 2025, as envisaged under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended to-date.

**For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED**

**Place: Ujjain
Date: August 11, 2025**

**Sd/-
NAVIN JHAWAR
JT. MANAGING DIRECTOR
DIN: 08729821**

**Sd/-
ARPIT BANGUR
MANAGING DIRECTOR
DIN:02600716**

MD/CFO CERTIFICATION

Certification Pursuant to Regulation 17(8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We, Arpit Bangur, Managing Director and Ankita Jain, Chief Financial Officer of Raaj Medisafe India Limited do hereby certify to the Board that:-

- a) We have reviewed Financial Statements and the Cash Flow Statement of the Company for the year ended March 31, 2025 and that to the best of our knowledge and belief:
 - i. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - ii. these statements together present a true and fair view of the Company's affair and are in compliance with existing Accounting Standards, applicable laws and regulations.
- b) To the best of our knowledge and belief, no transactions entered into by the Company during the year ended March 31, 2025 are fraudulent, illegal or violative of the Company's code of conduct.
- c) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. We have not come across any deficiencies in the design or operation of such internal controls.
- d) During the year: -
 - i. there have not been any significant changes in internal control over financial reporting;
 - ii. there have not been any significant changes in accounting policies and that the same have been disclosed in the notes to the financial statements; and
 - iii. there have been no instances of significant fraud of which we are aware that involve management or other employees have significant role in the Company's internal control system over financial reporting.

Place : Ujjain
Date: May 29, 2025

CA. ANKITA JAIN
Chief Financial Officer

ARPIT BANGUR
Managing Director

ANNEXURE – ‘C’
ANNEXURE TO THE DIRECTOR'S REPORT 2024-25

Particulars of contracts/arrangements entered into by the company with related parties

Form AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014) for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013

1. Details of contracts or arrangements or transactions not at arm's length basis

Name(s) of the related party and nature of relationship (a)	Nature of contracts/ arrangements/ transactions (b)	Duration of the contracts / arrangements/ transactions (c)	Salient terms of the contracts or arrangements or transactions including the value, if any (d)	Justification for entering into such contracts or arrangements or transactions (e)	Date of approval by the Board (f)	Amount paid as advances, if any (g)	Date on which the special resolution was passed in general meeting as required under first proviso to section 188 (h)
Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

1. Details of contracts or arrangements or transactions not at arm's length basis

Name(s) of the related party and nature of relationship (a)	Nature of contracts/ arrangements / transactions (b)	Duration of the contracts / arrangements / transactions (c)	Salient terms of the contracts or arrangements or transactions including the value, if any (d) (Rs. In Thousand)	Date(s) of approval by the Board, if any (e)	Amount paid as advances, if any (f) (Rs.)
Shriji Polymers (India) Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	4444.80	08.04.2024	Nil
	Sale of Goods		96477.45	08.04.2024	Nil
Vyanktesh Corrugators Pvt Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	1529.73	08.04.2024	Nil
	Sale of Goods		436.03	08.04.2024	Nil
Arpit Plastics Pvt Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	1391.48	08.04.2024	Nil
	Sale of Goods		1449.53	08.04.2024	Nil
Shree Packers (MP) Pvt Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	2240.75	08.04.2024	Nil
	Sale of Goods		7516.97	08.04.2024	Nil
Four M Propack Pvt Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	3849.28	08.04.2024	Nil
	Sale of Goods		7981.02	08.04.2024	Nil
Shriniwas Polyfabrics and Packwell Pvt Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	8422.23	08.04.2024	Nil

	Sale of Goods		100777.29	08.04.2024	Nil
Parekhplast India Limited	Sale of Goods	01.04.2024 to 31.03.2025	8756.94	08.04.2024	Nil
Ariba Foods Pvt Ltd.	Sale of Goods	01.04.2024 to 31.03.2025	180.41	08.04.2024	Nil
Narsingh Transport	Freight Charges Paid	01.04.2024 to 31.03.2025	2441.10	08.04.2024	Nil
Ujjain Security and Man Power Services Pvt Ltd.	Security Service Charges Paid	01.04.2024 to 31.03.2025	653.23	08.04.2024	Nil
Four M Propack Pvt Ltd.	Purchase of Goods	01.04.2024 to 31.03.2025	35.40	08.04.2024	Nil
Arpit Plastics Pvt Ltd.	Purchase of Fixed Assets	01.04.2024 to 31.03.2025	248.50	08.04.2024	Nil
Four M Propack Pvt Ltd.	Purchase of Fixed Assets	01.04.2024 to 31.03.2025	13704.52	08.04.2024	Nil
Shriji Polymers (India) Limited	Purchase of Fixed Assets	01.04.2024 to 31.03.2025	953.14	08.04.2024	Nil
Vyanktesh Plastics and Packaging Pvt Ltd.	Sale of Fixed Assets	01.04.2024 to 31.03.2025	6000.00	08.04.2024	Nil
Shri Arpit Bangur	Remuneration	01.04.2024 to 31.03.2025	3000.00	-	Nil
Shri Navin Jhawar	Remuneration	01.04.2024 to 31.03.2025	2478.00	-	Nil
Smt. Shweta Jajoo	Remuneration	01.04.2024 to 31.03.2025	1260.00	-	Nil
Smt. Ankita Jain	Remuneration	01.04.2024 to 31.03.2025	653.28	-	Nil
Shri Sachin Sarda	Remuneration	01.04.2024 to 31.03.2025	378.00	-	Nil

The above transactions entered into by the Company with related parties are in the ordinary course of business and on arm's length basis.

Notes:

S. No.	Name of the Company/Firm/Person	Relationship
1.	Shriji Polymers (India) Ltd.	Shri Arpit Bangur through his relatives
2.	Vyanktesh Corrugators Pvt Ltd.	Shri Arpit Bangur through his relatives
3.	Arpit Plastics Pvt Ltd.	Shri Arpit Bangur through his relatives
4.	Shree Packers (MP) Pvt Ltd.	Shri Arpit Bangur is Director and Shareholders
5.	Four M Propack Pvt Ltd.	Shri Arpit Bangur through his relatives
6.	Shrinivas Polyfabrics and Packwell Pvt Ltd.	Shri Arpit Bangur and his relatives are shareholders
7.	Parekhplast India Limited	Shri Arpit Bangur through his relatives
8.	Ariba Foods Pvt Ltd.	Shri Arpit Bangur is a Director and Shareholder.
9.	Narsingh Transport	Shri Arpit Bangur is a Partner
10.	Ujjain Security and Man Power Services Pvt Ltd.	Shri Hemant Kasliwal is a Director
11.	Vyanktesh Plastics and Packagings Pvt Ltd.	Shri Arpit Bangur through his relatives
12.	Shri Arpit Bangur	Shri Arpit Bangur is Managing Director of the company

13.	Shri Navin Jhavar	Shri Navin Jhavar is Whole Time Director of the company
14.	Smt. Shweta Jajoo	Smt. Krishna Jajoo through her relative.
15.	Smt. Ankita Jain	Smt. Ankita Jain is CFO of the company
16.	Shri Sachin Sarda	Shri Sachin Sarda is Company Secretary and Compliance Officer of the company

**For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED**

**Place: Ujjain
Date: August 11, 2025**

**Sd/-
NAVIN JHAWAR
JT. MANAGING DIRECTOR
DIN: 08729821**

**Sd/-
ARPIT BANGUR
MANAGING DIRECTOR
DIN:02600716**

ANNEXURE – ‘D’

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo – 2024-25

[Section 134(3)(m) of The Companies Act, 2013 read with Rule 8(3) of The Companies (Accounts) Rules, 2014]

Conservation of energy

S.No.	Particulars		
i.	the steps taken or impact on conservation of energy;	All efforts are made to conserve and optimize use of energy with continuous monitoring, improvement in maintenance and distribution systems and through improved operational techniques.	
ii.	the steps taken by the company for utilizing alternate sources of energy;	The Company has installed Solar Plant of 200KVA in its Unit II which started functioning during July, 2024	
iii.	the capital investment on energy conservation equipments	NIL	NIL
Technology absorption			
(i)	the efforts made towards technology absorption	The Company has not set up R & D Department. However, Updation of in house Technology is a Continuous process, absorption implemented in our Industry.	
(ii)	the benefits derived like product improvement, cost reduction, product development or import substitution	The Company has been able to successfully indigenize the toolings to a large extent. Increased efficiency, better performance and wider product range.	
(iii)	in case of imported technology (imported during the last three years reckoned from the beginning of the financial year	NIL	
	(a) the details of technology imported	NA	
	(b) the year of import	NA	
	(c) whether the technology has been fully absorbed	NA	
	(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and	NA	
(iv)	the expenditure incurred on Research and Development	NIL	NIL
Rs. (In thousands)			
Foreign exchange earnings and Outgo		2024 -25	2023 -24
(i)	The Foreign Exchange earned in terms of actual inflows during the year;	232.185	86.62
(ii)	The Foreign Exchange outgo during the year in terms of actual outflows.	0.00	0.00

**For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED**

Sd/-

**Place: Ujjain
Date: August 11, 2025**

**NAVIN JHAWAR
JT. MANAGING DIRECTOR
DIN: 08729821**

Sd/-

**ARPIT BANGUR
MANAGING DIRECTOR
DIN:02600716**

ANNEXURE – ‘E’
PARTICULARS OF EMPLOYEES

The applicable information required pursuant to Section 197 of the Companies Act, 2013 read with Rule (5) of the Companies (Appointment and Remuneration of Managerial Personnel), Rules 2014 in respect of the employees are as under.

- I. The percentage increase in remuneration of each Director, Chief Financial Officer, and Company Secretary, during the Financial year 2024-25, the ratio of the remuneration of each Director to the median remuneration of employees of the Company for the Financial year 2024-25 are as under: (Amount in Thousand Rupees)

(Amount in Thousand Rupees)

S. No.	Name & Designation	Designation	Remuneration of Director/KMP for the FY 2024-25	% Increase in Remuneration in the FY 2024-25	The ratio of remuneration of each Director to the median remuneration of employees
1	Arpit Bangur	Director	30,00,000.00		NA
2	Navin Jhawar	Director	24,78,000.00	25%	NA
3	Ankita Jain	CFO	6,53,280.00	12%	NA
4	Sachin Sarda	CS	3,78,000.00	11%	NA

Sitting fee paid for attending the meetings of the Board and Committee.

- The median remuneration of employees of the Company during the financial year was Rs.151.46 Thousand. (calculated on the basis of employee worked for whole financial year)
 - In the financial year, there was 10 % increment, in the median remuneration of employees.
 - The number of permanent employees on the roll of the company are 122 Employees.
 - The Price earnings ratio as at 31.03.2025 is 16.00 and 31.03.2024 was 18.71.
 - All the components of the remuneration are fixed and no components are variable.
 - The remuneration paid to Managing Director and Jt. Managing Director is as per Schedule V of the Companies Act, 2013 and remuneration policy of the Company.
 - It is hereby affirmed that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.
- II. None of the employees of the company was in receipt of remuneration in excess of limits prescribed under Rule 5(2) read with Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

**For and on behalf of the Board
RAAJ MEDISAFE INDIA LIMITED**

Sd/-

NAVIN JHAWAR

JT. MANAGING DIRECTOR

DIN: 08729821

Sd/-

ARPIT BANGUR

MANAGING DIRECTOR

DIN:02600716

Place: Ujjain

Date: August 11, 2025

Form No. MR-3**SECRETARIAL AUDIT REPORT****FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025****[Pursuant to section 204 (1) of the Companies Act, 2013 and rule No. 9 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014]**

To,

The Members,

Raaj Medisafe India Limited

CIN: L33112MP1985PLC003039

75/2 and 3, Industrial Area, Maksi Road,

Ujjain MP 456010 IN

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Raaj Medisafe India Limited** (hereinafter called the company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended **March 31, 2025** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by Company for the financial year ended on March 31, 2025 according to the provisions of:

- i. The Companies Act, 2013 (the Act) and the rules made thereunder read with notifications, exemptions and clarifications thereto;
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- iv. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended from time to time;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from

time to time;

- c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and as amended from time to time.
 - d. The Securities and Exchange Board of India (Share Based Employee Benefits and sweat Equity) Regulation. (Not Applicable to the Company during the Audit Period)
 - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008. (Not Applicable to the Company during the Audit Period)
 - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 as amended from time to time regarding the Companies Act and dealing with client;
 - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 as amended from time to time. (Not applicable to the Company during the reporting period under Audit)
 - h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018. (Not applicable to the Company during the reporting period under Audit)
- vi. We have relied on the representation made by the Company and its officers for system and mechanism framed by the Company for the compliances under the following applicable Act (if applicable), Law & Regulations to the Company
- i. Workmen's compensation Act, 1923 and all other allied labor laws, as informed / confirmed to us.
 - ii. Applicable Direct and Indirect Tax Laws.
 - iii. Prevention of Money Laundering Act, 2002
 - iv. Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to board and general meetings.
- (ii) SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

During the period the company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that, the compliance by the Company of applicable financial laws such as direct and indirect tax laws and maintenance of financial records and books of accounts have not been reviewed in this Audit since the same have been subject to review by the statutory financial auditors, tax auditors, and other designated professionals.

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance other than those held at shorter notice, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the Minutes of the meeting duly recorded and signed by the chairman, the decisions at the Board Meeting were taken unanimously and no dissenting views were recorded.

We further report that there are adequate systems and processes in the company commensurate with the size and

operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the Audit period, the Company had the following event which had a bearing on the Company's affairs in pursuance of the above-referred laws, rules, regulations, guidelines, and standards.

1. The Company pursuant to the Special Resolution passed by the members of the Company in the Extra-Ordinary General Meeting held on March 27, 2024, the Company has allotted 22,75,000 fully paid-up equity shares of ₹10 each at a premium of ₹34 per share for cash, on a preferential basis. The allotment was made on May 6, 2024, and the details were filed through Form PAS-3. The BSE Limited imposed a fine of ₹2,40,000 plus GST for delayed submission, which has been paid by the Company.

Note: This Report is to be read with our letter which is annexed as Annexure A which forms an integral part of this report.

For M. Maheshwari & Associates
Company Secretaries
Firms U.C.N. I2001MP213000

Sd/-
Manish Maheshwari
Proprietor
FCS-5174
CP-3860
PR NO. 1191/2021

Date : 7th August 2025
Place : Indore
UDIN : F005174G000955497

To,
The Members,
Raaj Medisafe India Limited
75/2 and 3, Industrial Area,
Maksi Road, Ujjain MP 456010 IN

Our Secretarial Audit Report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
4. Wherever required, we have obtained the Management representation about the compliances of laws, rules, regulations and happening of events etc.
5. The compliances of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy of effectiveness with which the management has conducted the affairs of the company.

For M. Maheshwari & Associates
Company Secretaries
Firms U.C.N. I2001MP213000

Sd/-
Manish Maheshwari
Proprietor
FCS-5174
CP-3860
PR NO. 1191/2021

Date : 7th August 2025
Place : Indore
UDIN : F005174G000955497

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS**"Annexure G"**

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Raaj Medisafe India Limited
75/2 and 3, Industrial Area, Maksi Road,
Ujjain MP 456010 IN

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Raaj Medisafe India Limited having CIN: L33112MP1985PLC003039 and having Registered office at 75/2 and 3, Industrial Area, Maksi Road, Ujjain MP 456010 IN (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ended on 31st March, 2025 have been debarred or disqualified from being appointed or continuing as Directors of the Company by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

S. No.	Name of Director	DIN	Date of Appointment in Company	Date of Cessation in Company
1.	Mr. Arpit Bangur	02600716	13.05.2013	-
2.	Mr. Navin Jhawar	08729821	18.08.2021	-
3.	Mrs. Krishna Jajoo	02590793	15.01.2015	-
4.	Mr. Rajesh Kumar Gupta	00774786	08.09.2011	25.09.2024
5.	Mr. Vijendra Kumar Sood	02612644	01.03.2013	25.09.2024
6.	Mr. Rakesh Agrawal	09675176	09.08.2022	-
7.	Mr. Hemant Kasliwal	01797300	14.08.2024	-
8.	Mr. Ateet Agrawal	05167866	14.08.2024	-

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For M. Maheshwari & Associates
Company Secretaries
Firms U.C.N. I2001MP213000

Sd/-
Manish Maheshwari
Proprietor
FCS-5174
CP-3860
PR NO. 1191/2021

Date : 7th August 2025
Place : Indore
UDIN : F005174G000955486

Independent Auditor's Report

To
The Members of
Raaj Medisafe India Limited

Report on the audit of the IND AS Financial Statements**Opinion**

We have audited the accompanying IND AS Financial Statements of **Raaj Medisafe India Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2025, and the Statement of Profit and Loss and Statement of Cash flows and notes to the IND AS Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid IND AS Financial Statements give the information required by the **Companies Act, 2013** ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025 and its Statement of Profit and Loss account and Statement of Cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the IND AS Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the IND AS Financial Statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone IND AS Financial Statements of the current period. These matters were addressed in the context of our audit of the IND AS Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Sr. No.	Key Audit Matter	Auditors Response
1.	Accuracy of recognition measurement, presentation and disclosures of revenues and other related balances in view of adoption of INDAS 115	<p>We assessed the company's process to identify the impact of the existing revenue accounting policy</p> <p>Our audit approach consisted testing of the design and operating effectiveness of the internal controls and substantive testing as follows:</p> <p>i. We have reviewed the Company's Accounting policies for Revenue Recognition (Refer Note No. 1 of the standalone financial statements).</p> <p>ii. We have carried out substantive procedures on sample basis for evaluation of operating effectiveness and each income stream, basis of management estimation and their corresponding disclosure.</p>

Information other than the IND AS Financial Statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Director's Report and other company related information, but does not include the standalone INDAS Financial Statements and our auditor's report thereon.

Our opinion on the IND AS Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the IND AS Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the IND AS Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's responsibility for the IND AS Financial Statements

The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these IND AS Financial Statements that give a true and fair view of the financial position and financial performance and Cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the IND AS Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the IND AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the IND AS Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these IND AS Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the IND AS Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and

related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the IND AS Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the IND AS Financial Statements, including the disclosures, and whether the IND AS Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other legal and regulatory requirements

1. As required by section 197(16) of the Act based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act, 2013.
2. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
3. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid IND AS Financial Statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 Companies Accounts Rules 2015 as amended except for INDAS 107 re. Financial Instruments Disclosures;
 - (e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the board of directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act;
 - (f) With respect to the adequacy of the internal financial controls with reference to IND AS Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report.
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;

- i. The company has disclosed the impact of the pending litigations on its financial position in its IND AS Financial Statements- Refer Note No. 32 to the INDAS Financial Statements.
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
- iii. There were no amounts which required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
 - (a) Management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes no 37A to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) Management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes no.37A to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. During the year the company has not declared or paid any interim and final dividend by the company.
- vi. As stated in note 39 to the financial statements and based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated from 3rd April 2023 for relevant transactions recorded in the software.

For V.K. Ladha & Associates
Chartered Accountants
FRN 002301C

Sd/-
CA. V. K. Ladha
Partner
M.No. 071501

UDIN : 25071501BMIFZF7727
Place : Ujjain
Date : 29th May, 2025

ANNEXURE 'A' TO INDEPENDENT AUDITOR'S REPORT

Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date to the Auditor of Raaj Medisafe India Limited, on the Ind AS financial statements for the year ended 31st March 2025

In terms of the information and explanations given to us and the books and records of the Company examined by us in the normal course of audit and to the best of our knowledge and belief, we state that

- I. (a) As per information and explanations given to us, the Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;
- (b) As per information and explanations given to us, Property, Plant and Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification;
- (c) The title deeds of all the immovable properties disclosed in the financial statements are held in the name of the company.
- (d) The Company has not revalued any of its property, plant and equipment (including Right of Use assets) or intangible assets or both during the year
- (e) As per information and explanations given to us, no proceedings have been initiated or are pending against the company as at 31st March, 2025 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under.
- ii. (a) As per information and explanations given to us, the inventories were physically verified during the year by the Management at reasonable intervals. In our opinion the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No material discrepancies were noticed on such physical verification of inventories when compared with books of accounts.
- (b) During the year, the Company has been sanctioned working capital limits in excess of Rs. 5.00 crores, in aggregate, from banks on the basis of security of current assets. The Company has filed quarterly returns or statements with such banks, there were no material variation observed with the audited books of account.
- iii. (a) The Company has made investments in one company and advances in nature of loans (advances) to parties. The aggregate amount during the year, and balance outstanding at the balance sheet date with respect to such loans or advances and guarantees or security to subsidiaries, joint ventures and associates and to parties other than subsidiaries, joint ventures and associates are as per the table given below:

The Company has provided loans, during the year and details of which are given below:

A. Aggregate amount granted / provided during the year:	Loans (Rs.in crores)
Related Party	2.92
Others	0.00
B. Balance outstanding as at balance sheet date in respect of above cases:*	
Related Party	2.83

- (b) According to the information and explanations given to us, the investments made, guarantees provided, security given and the terms and conditions of the grant of all loans and advances in the nature of loans and guarantees provided are not prima facie prejudicial to the company's interest;
- (c) There is no stipulation of schedule of repayment of principal and payment of interest and therefore we are unable to

comment on the regularity of repayment of principal & payment of interest.

- (d) There is no stipulation of schedule of repayment of principal and payment of interest and therefore we are unable to comment whether the amount is overdue or not.
 - (e) There were no loans/advances in nature of loans which fell due during the year.
 - (f) The company has granted loan to one party i.e M/s Shriniwas Polyfabric and Packwell Pvt. Ltd. amount of Rs. 2.92 crores which was repaid at the year end and balance is Rs.2.83 crores or no advances are in the nature of loans either repayable on demand or without specifying any terms or period of repayment.
- iv. In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of the loans and investments made. The Company has not provided any guarantees and security to the parties covered under Sections 185 and 186 of the Companies Act, 2013.
- v. The company has not accepted any deposits or amounts which are deemed to be deposits covered under sections 73 to 76 of the Companies Act, 2013. Hence, reporting under clause (v) of the Order is not applicable.
- vi. As per information & explanation given by the management, the Company is maintained cost records which is specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for the business activities carried out by the company.
- vii. According to the information and explanations given to us, in respect of statutory dues:
- (a) According to the records made available to us, company is generally regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. According to the information and explanation given to us there were no outstanding statutory dues as on 31st of March, 2025 for a period of more than six months from the date they became payable.
 - (b) According to the information and explanation given to us there are no dues of Income Tax, Goods and Service Tax, VAT, sales tax which have not been deposited by the Company on account of disputes except of the following:-

Nature of the Statute	Nature of Dues	Amount (in lacs)	Period to which the Amount relates	Forum where dispute is pending
Income Tax	Income Tax	5.68	2018-19	Commissioner of Income Tax (Appeal), Bhopal

- viii. According to the information and explanations given by the management, no transactions recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- ix. (a) In our opinion and according to the information and explanations given by the management, we are of the opinion that the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given by the management, the company has not been declared willful defaulter by any bank or financial institution or other lender;
- (c) In our opinion and according to the information and explanations given by the management, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained,

- (d) In our opinion and according to the information and explanations given by the management, funds raised on short term basis have not been utilized for long term purposes.
- (e) In our opinion and according to the information and explanations given by the management, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures,
- (f) In our opinion and according to the information and explanations given by the management the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Hence reporting on clause (ix) (f) of the Order is not applicable.
- x. (a) The company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year. Hence reporting on clause (x)(a) of the Order is not applicable.
- (b) The company has made any preferential allotment i.e. the Board of Directors of the Company in its meeting held on May 6, 2024 has allotted 2275000 Fully paid up equity shares of Rs.10 each at a premium of Rs.34 per share on Preferential basis to Promoter Group and other non promoter group in accordance with provisions of Chapter V of SEBI (ICDR) Regulations, 2018. Further, the Company has not made any private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.
- xi. (a) According to the information and explanations given by the management, no fraud by the company or any fraud on the company has been noticed or reported during the year.
- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) According to the information and explanations given to us by the management, no whistle- blower complaints had been received by the company.
- xii. The company is not a Nidhi Company. Therefore, clause xii is not applicable on the company.
- xiii. In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed by the management in the IND AS Financial Statements & notes to accounts as required by the applicable accounting standards.
- xiv. (a) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business which need to be further strengthen.
- (b) We have considered the Internal Audit Reports issued to the Company during the year and covering the period up to 31 March 2025 for the period under audit.
- xv. On the basis of the information and explanations given to us, in our opinion, during the year the company has not entered into any non-cash transactions with directors or persons connected with him. Hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. (a) In our Opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934).The company is not a core investment company, hence, reporting under clause (xvi)(a), (b) and (c) of the Order is not applicable.
- xvii. Based on our examination, the company has not incurred cash losses in the financial year and in the immediately preceding financial year.

- xviii. There has been no resignation of the statutory auditors of the Company during the year.
- xix. On the basis of information obtained from the management and audit procedures performed and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- xx. Based on our examination, the provision of section 135 is not applicable on the company. Hence this clause is not applicable on the company.
- xxi. The company is not required to prepare Consolidate financial statement hence this clause is not applicable.

For V.K. Ladha & Associates
Chartered Accountants
(Firm Reg. No. 002301C)

UDIN : 25071501BMIFZF7727
Place : Ujjain
Date : 29th May, 2025

Sd/-
CA. V. K. Ladha
Partner
M.No. 071501

ANNEXURE "B" TO INDEPENDENT AUDITORS' REPORT**Report on the internal financial controls with reference to the aforesaid Ind AS financial statements under Section 143(3)(I) of the Companies Act, 2013**

(Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

We have audited the internal financial controls with reference to Ind AS financial statements over financial reporting of Raaj Medisafe (India) Limited ("the Company") as of 31st March 2025 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls with reference to Ind AS financial statements based on the internal controls over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by The Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to Ind AS financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Ind AS financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system with reference to Ind AS financial statements and their operating effectiveness. Our audit of internal financial control with reference to Ind AS financial statements included obtaining an understanding of internal financial control with reference to Ind AS financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to Ind AS financial statements.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) Pertain to the maintenance of records that, in reasonable detail, accurately and

fairly reflect the transactions and dispositions of the assets of the Company; (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the Ind AS financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an internal financial controls system over financial reporting and such internal financial controls over financial reporting were needs to be strengthen as at 31st March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For V.K. Ladha & Associates
Chartered Accountants
(Firm Reg. No. 002301C)

UDIN: : 25071501BMIFZF7727
Place : Ujjain
Date : 29th May, 2025

Sd/-
CA. V. K. Ladha
Partner
M.No. 071501

BALANCE SHEET AS AT 31ST MARCH, 2025
(Rs. In 000)

PARTICULARS		Note No.	As At 31.03.2025	As At 31.03.2024
I.	ASSETS			
	<u>Non-current Assets</u>			
	(a) Property, Plant and Equipment	4	230,600.97	107,232.04
	(b) Intangible assets	4	0.10	0.10
	(c) Capital Work In Progress	4A	85,055.74	101,419.83
	(d) Financial assets			
	(i) Investments			
	(a) Investments in subsidiaries, associates, JV			
	(b) Other Investments	5	730.10	730.10
	(ii) Other Financial Assets	6	6,217.97	1,543.63
	(e) Deferred tax assets (net)		11,580.98	-
	(f) Other non - current assets	7	61,794.75	16,988.12
	(2) <u>Current assets</u>			
	(a) Inventories	8	81,422.34	84,638.43
	(b) Financial assets			
	(i) Investments			
	(ii) Trade receivables	9	166,951.58	78,892.82
	(iii) Cash and cash equivalents	10	516.13	321.13
	(iv) Bank balances other than cash and cash equivalents	11	132.70	132.70
	(v) Others		0.00	
	(c) Other current assets	12	47,161.40	20,955.48
	Total Assets		692,164.77	412,854.38
II.	EQUITY AND LIABILITIES			
	(1) <u>Equity</u>			
	(a) Equity Share capital	13	131,786.12	109,036.12
	(b) Other equity	14	137,368.10	-668.95
	Liabilities			
	(2) <u>Non - current liabilities</u>			
	(a) Financial liabilities			
	(i) Long Term Borrowings	15	143,716.74	138,443.71
	(ii) Lease Liability		619.00	552.73
	(iii) Other Financial Liabilities		0.00	0.00
	(b) Deferred Tax Liability (net)		0.00	6,665.32
	(3) <u>Current liabilities</u>			
	(a) Financial liabilities			
	(i) Short Term Borrowings	16	201,341.56	120,267.00
	(ii) Lease liabilities		5.72	5.72
	(iii) Trade payables	17		
	a) Total outstanding dues of micro enterprises and small enterprises		768.01	928.37
	b) Total outstanding dues of creditors others than micro enterprises and small enterprises		42,161.70	6,183.45
	(iii) Other financial liabilities	18	7,067.15	3,246.26
	(b) Provisions	19	16,244.05	12,933.89
	(c) Other current liabilities	20	11,086.60	15,260.77
	Total Equity and Liabilities		692,164.77	412,854.38

Significant accounting policies and estimates the accompanying notes 1 to 39 are an integral part of the financial statement

As per our report on even date annexed.

For V.K.Ladha & Associates

Chartered Accountants
Firm Regn. No. 002301C

Sd/-

For CA V. K. Ladha
Membership No. 071501
Partner
Ujjain, 29th May, 2025
UDIN:25071501BMIFZF7727

Sd/-

Arpit Bangur
Managing Director
(DIN-02600716)

Sd/-

Ateet Agarwal
Director
(DIN-05167866)

Sd/-

Navin Jhawar
Jt. Managing Director
(DIN-08729821)

Sd/-

Rakesh Agrawal
Director
(DIN-09675176)

For and on behalf of Board of Directors

For Raaj Medisafe India Limited

Sd/-

Hemant Kasliwal
Chairman - Audit Committee
(DIN-01797300)

Sd/-

CS Sachin Sarda
Company Secretary
(M. No.20930)

Sd/-

CA Ankita Jain
Chief Financial Officer
(M.No.426121)

Ujjain, 29th May, 2025

**STATEMENT OF PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31ST MARCH, 2025**

(Rs. In 000)

PARTICULARS		Note No.	Period Ended 31.03.2025	Year Ended 31.03.2024
I.	Revenue from operations	21	624,204.43	432,488.09
II.	Other income	22	1,989.98	602.19
III.	Total Income (I+II)		626,194.41	433,090.28
IV.	Expenses:			
	Cost of materials consumed	23	430,303.65	304,950.96
	Purchase of Traded Goods		14,629.93	-
	Changes in inventories of finished goods, by-products and work in progress	24	-7,116.54	-12,337.82
	Employee benefits expense	25	39,193.64	32,475.31
	Finance costs	26	21,280.74	15,656.18
	Depreciation and amortization expense		14,484.87	8,370.66
	Other expenses	27	60,869.96	41,085.28
	Total expenses (IV)		573,646.25	390,200.58
V.	Profit before tax (III-IV)		52,548.15	42,889.70
VI.	Exceptional Items	28	0.00	0.00
VII.	Tax expense :			
	Current tax		8,819.56	6,701.84
	Deferred tax		-18,246.30	2,902.54
	Income tax relating to earlier years		662.46	0.00
			-8,764.29	9,604.37
VIII.	Profit for the year		61,312.44	33,285.32
IX	Other comprehensive income	29		
	(i) Items that will not be reclassified to profit or loss		-625.39	167.64
	Remeasurement of the net defined benefit			
	(ii) Income tax relating to items that will not be reclassified to profit or loss		0.00	0.00
	Total other comprehensive income, net of tax			
X.	Total comprehensive income for the year		60,687.05	33,452.96
XI.	Earnings per equity share			
	- Basic		4.60	3.07
	- Diluted		4.60	3.07
	Significant accounting policies and estimates	1		
	The accompanying notes 1 to 39 are an integral part of the financial statement.			

For and on behalf of Board of Directors
For Raaj Medisafe India Limited

As per our report on even date annexed.

For V.K.Ladha & Associates
Chartered Accountants
Firm Regn. No. 002301C

Sd/-
Arpit Bangur
Managing Director
(DIN-02600716)

Sd/-
Navin Jhavar
Jt. Managing Director
(DIN-08729821)

Sd/-
Hemant Kasliwal
Chairman - Audit Committee
(DIN-01797300)

Sd/-
For CA V. K. Ladha
Membership No. 071501
Partner
Ujjain, 29th May, 2025
UDIN:25071501BMIFZF7727

Sd/-
Ateet Agarwal
Director
(DIN-05167866)

Sd/-
Rakesh Agrawal
Director
(DIN-09675176)

Sd/-
CA Ankita Jain
Chief Financial Officer
(M.No.426121)

Sd/-
CS Sachin Sarda
Company Secretary
(M. No.20930)

Ujjain, 29th May, 2025

STATEMENT OF CASH FLOW
FOR THE YEAR ENDED ON 31st MARCH 2025

(Rs. In 000)

PARTICULARS	As At 31.03.2025	As At 31.03.2024
A Cash flow from operating activities:		
Profit before tax	51922.8	43,057.34
Adjustments for :		
Depreciation and amortisation expense	14484.9	8,370.66
Interest & Other finance Charges	21280.7	15,656.18
Interest income	-1931.3	-602.19
Dividend income on current investments	0.0	0.00
Profit on sale of Property, Plant and Equipments	0.0	0.00
Foreign Exchange Difference	0.0	-11.57
Sundry Balances W/o	0.0	0.00
Operating profit before working capital changes	85757.07	66,470.42
Adjustments for changes in working capital :		
(Increase) in Trade Receivables	-88058.76	-12,630.99
Decrease/(Increase) in Inventories	3216.09	-18,528.41
(Increase) in Financial Assets	-4869.59	-
(Increase) in Other Assets	-26205.92	-3,829.03
Increase/(Decrease) in Trade Payables	35817.90	-706.76
Increase in Other Liabilities	-864.00	14,546.13
Increase in Financial Liabilities	3820.89	4,129.74
Cash flow from/ (Used in) operations	8613.67	49,451.11
Income Taxes Paid	-9482.01	-6,701.84
Net cash flow from/(Used in) operating activities	-868.34	42,749.27
B Cash flow from investing activities:		
Purchase of Property, Plant and Equipments (including capital work-in-progress, capital advances and intangibles under development)	-147096.23	-116,390.35
Proceeds from sale of Property, Plant and Equipments	17912.97	0.00
Subsidy Received against purchase of Property, Plant and Equipments	7888.80	444.00
Purchase of Investments	0.0	0.00
Proceeds from sale of Investments	0.0	0.00
Net proceeds (to)/from loans and advances	-44806.63	-14,661.60
Net proceeds (to)/from Deposits	0	0.00
Dividend Received	0	0.00
Interest Received	1931.31	602.19
Net cash (used in)/flow from investing activities	-164169.78	-130,005.75
C Cash flow from financing activities:		
Net (repayment)/proceeds from Current Borrowings	81074.56	29,912.40
Proceeds from Non-Current Borrowings	5339.31	73,171.47
Change in Issued Share Capital	100100.00	6.00
Repayment of Non-Current Borrowings	0.00	0.00
Interest & Other Finance Charges Paid	-21280.74	-15,656.18
Net cash (Used in)/flow from financing activities:	165233.12	87,433.69
D Net increase/(Decrease) in cash and cash equivalents	195.00	177.21
Cash and cash equivalents at the beginning of the year	453.83	265.06
Cash And Cash Equivalents at the end of the year	648.83	442.27
E Cash And Cash Equivalents comprises of:		
Balances with banks on current accounts	132.70	132.70
Cash on hand	516.13	321.13
Deposits with maturity less than 3 months	0	0.00
Add : Foreign Exchange Gain	0	11.57
	0.00	0.00

For and on behalf of Board of Directors
For RaaJ Medisafe India Limited

As per our report on even date annexed.

For V.K.Ladha & Associates

Chartered Accountants
Firm Regn. No. 002301C

Sd/-
Arpit Bangur
Managing Director
(DIN-02600716)

Sd/-
Navin Jhawar
Jt. Managing Director
(DIN-08729821)

Sd/-
Hemant Kasliwal
Chairman - Audit Committee
(DIN-01797300)

Sd/-
For CA V. K. Ladha
Membership No. 071501
Partner
Ujjain, 29th May, 2025
UDIN:25071501BMIFZF7727

Sd/-
Ateet Agarwal
Director
(DIN-05167866)

Sd/-
Rakesh Agrawal
Director
(DIN-09675176)

Sd/-
CA Ankita Jain
Chief Financial Officer
(M.No.426121)

Sd/-
CS Sachin Sarda
Company Secretary
(M. No.20930)

Ujjain, 29th May, 2025

**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31ST MARCH, 2025**

A. Equity Share Capital

(Number of Shares)

Particular	Balance at the beginning of the year	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the reporting year	Changes in equity share capital during the year	Balance at the end of the year
For the year ended 31st March, 2024	10937612			0	10937612
For the year ended 31st March, 2025	10937612	0	0	2275000	13212612

(b) Other Equity

(Rs. In 000)

Particulars	Reserves and Surplus				Items of Other Comprehensive Income	
	Capital Reserve	Investment Allowance Reserves	Securities premium	Retained Earnings	Re-measurement of defined benefit plan	Total
Balance as at 1st April, 2024	2,500.00	4,230.75	22,452.25	-30,213.30	361.36	-668.95
Changes in accounting policy or prior period errors	0.00	0.00	0.00	0.00	0.00	0.00
Restated balance as on 01.04.2024	2,500.00	4,230.75	22,452.25	-30,213.30	361.36	-668.95
Profit for the year	0.00	0.00	0.00	61,312.44	-625.39	60,687.05
Share Premium received on issue of Preferential shares	0.00	0.00	77,350.00	0.00	0.00	77,350.00
Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00
Total Comprehensive Income for the year	0.00	0.00	0.00	61,312.44	-625.39	60,687.05
Transfer from retained earnings	0.00	0.00	0.00	0.00	0.00	0.00
Transfer to general reserve	0.00	0.00	0.00	0.00	0.00	0.00
Final Dividend	0.00	0.00	0.00	0.00	0.00	0.00
Balance As at 31st March, 2025	2,500.00	4,230.75	99,802.25	31,099.14	-264.02	137,368.10
Balance as at 1st April, 2023	2,500.00	4,230.75	22,452.25	-63,666.27	361.36	-34,121.91
Changes in accounting policy or prior period errors	0.00	0.00	0.00	0.00	0.00	0.00
Restated balance as on 01.04.2023	2,500.00	4,230.75	22,452.25	-63,666.27	361.36	-34,121.91
Profit for the year	0.00	0.00	0.00	33,452.96	0.00	33,452.96
Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00
Total Comprehensive Income for the year	0.00	0.00	0.00	33,452.96	0.00	33,452.96
Transfer from retained earnings	0.00	0.00	0.00	0.00	0.00	0.00
Transfer to general reserve	0.00	0.00	0.00	0.00	0.00	0.00
Final Dividend	0.00	0.00	0.00	0.00	0.00	0.00
Balance As at 31st March, 2024	2,500.00	4,230.75	22,452.25	-30,213.30	361.36	-668.95

For and on behalf of Board of Directors
For RaaJ Medisafe India Limited

As per our report on even date annexed.

For V.K.Ladha & Associates

Chartered Accountants
Firm Regn. No. 002301C

Sd/-
Arpit Bangur
Managing Director
(DIN-02600716)

Sd/-
Navin Jhavar
Jt. Managing Director
(DIN-08729821)

Sd/-
Hemant Kasliwal
Chairman - Audit Committee
(DIN-01797300)

Sd/-
For CA V. K. Ladha
Membership No. 071501
Partner
Ujjain, 29th May, 2025
UDIN:25071501BMIFZF7727

Sd/-
Ateet Agarwal
Director
(DIN-05167866)

Sd/-
Rakesh Agrawal
Director
(DIN-09675176)

Sd/-
CA Ankita Jain
Chief Financial Officer
(M.No.426121)

Sd/-
CS Sachin Sarda
Company Secretary
(M. No.20930)

Ujjain, 29th May, 2025

Notes to Financial Statements

For The Year Ended 31st March, 2025

1. Company Overview:

- A) Raaj Medisafe India Ltd. is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on Bombay Stock Exchange (BSE) in India. The registered office of the company is located at 75/2 and 75/3, Industrial Area Maxi Road, Ujjain 456010 (M.P.) and also works at address 106, Sector III, Industrial Area, Pithampur-454774, Dist - Dhar, Madhya Pradesh, 75/2 and 75/3, Industrial Area Maxi Road, Ujjain 456010 (M.P.), 46, Sector III, Industrial Area, Pithampur-454774, Dist. Dhar, Madhya Pradesh.
- B) The company's principal activity is to manufacture plastic bottles, caps & plugs, plastic liners, aluminum caps, Sanitary Napkins and Diaper.

2. Basis of Preparation:

- A) The financial statements of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under section 133 of the Companies Act, 2013 ("The Act") read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, Companies (Indian Accounting Standards) Amendment Rules, 2016 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
- B) The financial statements of the Company are prepared in accordance with the Indian Generally Accepted Accounting Principles (GAAP) on the accrual basis of accounting and historical cost convention except for certain material items that have been measured at fair value as required by the relevant Ind AS and explained in the ensuing policies below.
- C) The financial statements are presented in Indian Rupees ('INR') and all values are rounded to the nearest thousands, except otherwise indicated.

3. SIGNIFICANT ACCOUNTING POLICIES:

- A) **Property, Plant & Equipment (PPE)** - Property, plant and equipment is stated at acquisition or construction cost net of accumulated depreciation, amortization and accumulated impairment losses, if any. Property, plant and equipment acquired in a business combination are recognized at carrying amount before merger date. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance cost are charged to the Statement of Profit and Loss during the period in which they are incurred.

Gains or losses arising on retirement or disposal of property, plant and equipment are recognized in the Statement of Profit and Loss.

Property, plant and equipment which are not ready for intended use as on the date of Balance Sheet are disclosed as "Capital work-in-progress".

At balance sheet date, the Company assesses whether there is any indication that any property, plant and equipment and intangible assets with finite lives may be impaired. If any such impairment exists the recoverable amount of an asset is estimated to determine the extent of impairment, if any. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Intangible assets not yet available for use are tested for impairment annually at each balance sheet date, or earlier, if there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be

Notes to Financial Statements

For The Year Ended 31st March, 2025

less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of Profit and Loss

- B) Depreciation on PPE** - Depreciation is provided on a pro-rata basis on the straight line method based on estimated useful life prescribed under Schedule II to the Companies Act, 2013. Depreciation on additions to property, plant and equipment is provided on a pro-rata basis from the date of acquisition or installation or construction, when the asset is ready for intended use.

No asset is impaired during the year. In respect of an asset for which impairment loss, if any, is recognized, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

The residual values, useful lives and method of depreciation of property, plant and equipment is reviewed at each financial year end and adjusted, if appropriate.

- C) Inventories** - Inventories are valued after providing for obsolescence, as follows:

- I) Raw materials, stores and spare parts and packing material:

Lower of cost and net realizable value. Cost includes purchase price, other costs incurred in bringing the inventories to their present location and condition, and taxes for which credit is not available. However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. If the value of inventories is expected to be sold below cost then it is valued at NRV and deducted from the cost of the Main Product

- II) Work-in-progress, finished goods and stock in trade:

Lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity, but excluding borrowing costs. Cost of stock-in-trade includes cost of purchase and other cost incurred in bringing the inventories to the present location and condition. Cost is determined on a weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

- D) Cash Flows** – Cash Flow Statement is prepared by the “Indirect method” set out in Ind AS 7 on “Statement of Cash Flow” and presents the cash flow by operating, investing and financing activities of the company. Cash and Cash equivalents presented in Cash Flow Statement consist of Cash on Hand and demand deposits with banks.
- E) Investment in subsidiaries, associates and joint arrangements** – There is no subsidiary company of the company, also the company has neither obtained any economic benefit from its activities nor did the company entered into any joint arrangement with any entity. Hence, Ind AS 28, Ind AS 110, Ind AS 111 and Ind AS 112 are not applicable.
- F) Financial Instruments** - A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through the statement of profit and loss are recognized immediately in the statement of profit and loss.
- I) Financial Assets** -
- (a) The Company's financial assets comprise:
- i) Current financial assets mainly consist of trade receivables, cash and cash equivalents, bank balances,

Notes to Financial Statements**For The Year Ended 31st March, 2025**

fixed deposits with banks and financial institutions and other current loans, advances & receivables.

ii) Non-current financial assets mainly consist of financial investments in equity.

(b) Initial recognition and measurement of financial assets:

All regular way purchases or sales of financial assets are recognised and de-recognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

(c) Subsequent measurement of financial assets:

i) Cash and cash equivalents – Cash and cash equivalents consist of cash on hand & balances in current accounts held in the name of the company. During the year, if company has surplus funds for shorter period, as part of Company's cash management policy, it parks its surplus funds in short-term highly liquid instruments that are generally held for a period of three months or less from the date of acquisition. These short-term highly liquid instruments are readily convertible into known amounts of cash and are subject to insignificant risk of changes in value.

ii) Other Balances with Banks - Fixed deposits, either free or liened whose maturities are within a period of 12 months are part of the other bank balances. It also includes debit balances, if any, in loan accounts.

iii) Trade Receivables & Other Current Financial Assets—Trade receivables, loans & other current financial assets are initially recognized at fair value. Subsequently, trade receivable need to be held at amortised cost, using the effective interest rate (EIR) method net of any expected credit losses. The EIR is the rate that discounts estimated future cash income through the expected life of financial instrument.

iv) Equity Instruments - Equity instruments, which are held for trading, are classified as at FVTPL. Equity instruments included within the FVTPL category should be measured at fair value with all changes recognized in the statement of profit and loss. The unquoted equity shares should be fair valued on the basis of available fair value. Due to non-availability of fair value of unquoted equity shares, the same is being carried in financial statements at cost.

(d) **De-recognition of financial assets:**

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognized when: -

- i) The rights to receive cash flows from the asset have expired, or
- ii) The Company has transferred its contractual rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

On de-recognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in the statement of profit and loss if such gain or loss would have otherwise been recognised in the statement of profit and loss on disposal of that financial asset.

Notes to Financial Statements**For The Year Ended 31st March, 2025****II) Financial Liability -**

(a) The Company's financial liability comprise:

- i) Non-current financial liabilities mainly consist of borrowings.
- ii) Current financial liabilities mainly consist of trade payables, staff related and other payables.

(b) Subsequent measurement of financial liabilities:

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost at the end of subsequent reporting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest rate method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item.

(c) De-recognition of financial liabilities:

A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

III) Offsetting of financial instruments – Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

G) Provisions & Contingencies -

I) Provision - A provision is recognised for a present obligation (legal or constructive) as a result of past events if it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and in respect of which a reliable estimate can be made. The amount recognized as provisions are determined based on best estimate of the amount required to settle the obligation at the balance sheet date. These estimates are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

II) Contingent liability - A contingent liability is a possible obligation that arises from the past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

III) Contingent Assets - Contingent asset is not recognised in financial statements since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognised.

H) Foreign Exchange & Losses - Foreign currency transactions are recorded at the rates of exchange prevailing on the date of transaction. Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction.

Exchange differences arising on the settlement of monetary items at rates different from those at which they were initially recorded during the year or reported in previous financial statements, are recognised as income or expense in the year in

Notes to Financial Statements

For The Year Ended 31st March, 2025

which they arise.

- I) **Revenue Recognition** –The Company earns revenue primarily by sale of packaging items. Revenue is recognised upon transfer of control of promised products or services to customers in an amount that reflects the consideration which the Company expects to receive in exchange for those products or services.

The Company has applied Ind AS 115 which establishes a comprehensive framework for determining whether, how much and when revenue is to be recognised. Ind AS 115 replaces Ind AS 18 Revenue and Ind AS 11 Construction Contracts. The Company has adopted Ind AS 115 using the cumulative effect method. The effect of initially applying this standard is recognised at the date of initial application (i.e. April 1, 2018). The standard is applied retrospectively only to contracts that are not completed as at the date of initial application and the comparative information in the statement of profit and loss is not restated – i.e. the comparative information continues to be reported under Ind AS 18 and Ind AS 11. The impact of the adoption of the standard on the financial statements of the Company is insignificant.

Revenue is measured based on the transaction price, which is the consideration, adjusted for volume discounts, service level credits, performance bonuses, price concessions and incentives, if any, as specified in the contract with the customer. Revenue also excludes taxes collected from customers.

- J) **Interest Income**- Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.
- K) **Other Income** - Income are accounted for on accrual basis and accordingly company follows the Mercantile System of Accounting. Claims / refunds not ascertainable with reasonable certainty are accounted for on settlement basis.
- L) **Expenditure** – Expenses are accounted on accrual basis. Further Prior period items are accounted under exceptional items as per Ind AS 8 "Accounting policies, changes in estimates and errors".

M) Retirement and other employee benefits -

- a) **Defined contribution plan** - Employee benefits in the form of contribution to Provident Fund managed by Government Authorities and Employees State Insurance Corporation are considered as defined contribution plans and the same are charged to the statement of profit and loss for the year in which the employee renders the related service.
- b) **Defined benefit plan** -The liability or asset recognised in the balance sheet in respect of defined benefit gratuity plan is the present value of defined benefit obligations at the end of the reporting period less fair value of expected plan assets. The defined benefit obligation is calculated annually by actuaries through actuarial valuation using the projected unit credit method.

The Company recognises the following changes in the net defined benefit obligation as an expense in the statement of profit and loss:

- i) Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and
- ii) Net interest expense or income

Re-measurements, comprising of actuarial gains and losses, the effect of the asset ceiling (if any), and the return on plan assets (excluding net interest), are recognized immediately in the balance sheet with a corresponding debit or

Notes to Financial Statements

For The Year Ended 31st March, 2025

credit to retained earnings through OCI in the period in which they occur. Re-measurements are not reclassified to profit or loss in subsequent periods.

- c) Short term employee benefits - The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by employees are recognized as an expense during the period when the employees render the services. Further accumulated compensated absences, which are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service, are treated as short term employee benefits. The Company does not recognize the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date; they are to be accounted for on cash basis. Thus its effect on Profit and Loss of the company is not determined.
- d) Other long-term employee benefits - There is no such other long term employees benefit for which actuarial valuation is required. Hence no actuarial gain or loss is booked in statement of profit or loss.
- e) Termination Benefit - Termination benefits are payable when employment is terminated by the Company before the normal retirement date, or when an employee accepts voluntary redundancy in exchange for these benefits. The Company recognizes termination benefits at the earlier of the following dates:
 - i) When the Company can no longer withdraw the offer of those benefits; and
 - ii) When the Company recognizes costs for a restructuring that is within the scope of Ind AS 37 and Involves the payment of termination benefits.

N) Borrowing Cost- Borrowing cost directly attributable to acquisition and construction of assets that necessarily takes substantial period of time to get ready for their intended use or sale are capitalised as part of the cost of such assets up to the date when such assets are ready for intended use or sale. All other borrowing costs are expensed in the period in which they occur. Borrowing cost consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

O) Taxation - Income tax expense comprises current tax and deferred tax. Income tax expense is recognised in the statement of Profit and Loss except when they relate to items that are recognised outside profit and loss (whether in other comprehensive income or directly in equity), in which case tax is also recognised outside profit and loss. Current income taxes are determined based on respective taxable income of each taxable entity.

Deferred tax assets and liabilities are recognised for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective tax bases, and unutilised business loss and depreciation carry-forwards and tax credits. Such deferred tax assets and liabilities are computed separately for each taxable entity. Deferred tax assets are recognised to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses, depreciation carryforwards and unused tax credits could be utilised.

Deferred tax assets and liabilities are measured based on the tax rates that are expected to apply in the period when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date. Current and deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

P) Leases- The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains,

Notes to Financial Statements

For The Year Ended 31st March, 2025

a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified assets, the Company assesses whether:

- (i) The contract involves the use of an identified asset;
- (ii) The Company has avail substantially all of the economic benefits from use of the asset Through the period of the lease; and
- (iii) The Company has the right to direct the use of the asset.

As a lessee, the Company should recognize a right-of-use asset and a lease liability at the lease commencement date. The right of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right of- use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurement of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. Lease payments included in the measurement of the lease liability comprise the fixed payments, including in-substance fixed payments; the lease liability is measured at amortised cost using the effective interest method.

The company has used number of practical expedients while applying Ind AS 116: - Short-term leases, leases of low-value assets and single discount rate. The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The company has entered into a lease agreement with MPAKVN Limited, for factory Land at Pithampur, Indore (M.P.). The company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term as the lease payment is of very low –value.

The company has paid the upfront lease premium at the time of execution of the lease deed which is being amortizing over the period of lease term determined by the company under Ind AS 17, the same assessment of lease term would be acceptable under Ind AS 116. The amortisation of lease premium is as per Ind AS 116 as the company neither have purchase option of the factory land at the expiry of the lease term nor the title will be transfer in the name of the company at the end of lease term.

Q) Government grants and subsidies - Grants and subsidies from the Government are recognised when there is reasonable assurance that the grant / subsidy will be received and all attaching conditions will be complied with.

Grant or subsidy relating to an asset is credited to the respective Property Plant & Equipment by the company which is in line with Ind AS 20 "Accounting for government grants & disclosure of government assistance".

R) Related Party Transactions - Transactions entered by the company with the related parties, has been disclosed by way of notes as defined under Ind AS 24 "Related Party Disclosures". (Refer Note-34)

Notes to Financial Statements

For The Year Ended 31st March, 2025

- S) Earning Per Share** - As per Ind AS 33 "Earning per Share", Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Basic earnings per share is Rs 4.60 per share as compared to Rs 3.065 per share in previous year. Diluted earnings per share are computed by dividing the profit after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares. Diluted earning per share is Rs.4.60 per share as compared to Rs.3.065 per share in previous year.
- T) Classification of current / non-current assets and liabilities** – All assets and liabilities are presented as current or non-current as per the Company's normal operating cycle and other criteria set out in Schedule III of the Companies Act, 2013 and Ind AS 1 "Presentation of financial statements". Based on the nature of products and the time between the acquisition of assets for processing and their realisation, the Company has ascertained its operating cycle as 12 months for the purpose of current / non-current classification of assets and liabilities.
- U) Significant estimates and assumptions** –The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year relate primarily to defined benefit obligations, useful life of property, plant and equipment, revenue recognition, fair value measurement of financial instruments at the end of the reporting period.'

- I) Defined benefit obligations** - The cost of defined benefit gratuity plans is determined using actuarial valuations. The actuarial valuation involves making assumptions about discount rates, future salary increases, mortality rates and future pension increases. Due to the long-term nature of these plans, such estimates are subject to significant uncertainty.
- II) Useful life of property, plant and equipment** - The charge in respect of periodic depreciation is derived after determining an estimate of an asset's expected useful life and the expected residual value. Increasing an asset's expected life or its residual value would result in a reduced depreciation charge in the Statement of profit and loss. The useful lives of the Company's assets are determined by management at the time the asset is acquired and reviewed at least annually for appropriateness. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life, such as changes in technology.

The estimated useful lives are as mentioned below:

Type of asset	Useful Lives
Buildings	30 years
Leasehold Improvement	Lease term
Plant & Machinery	15 years
Computer Equipment	3 years

Notes to Financial Statements**For The Year Ended 31st March, 2025**

Furniture & Fixtures	10 years
Office Equipments	5 years
Electrical Installation	10 years
Vehicles	8 years

- III) **Revenue recognition** - Company provides various discounts, allowances and rebates to the customers. The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions.
- IV) **Classification of legal matters and tax litigation** – The litigation and claims to which the Company is exposed to, are assessed by management with assistance of the legal department and in certain cases with the support of external specialized lawyers. Disclosures related to such provisions, as well as contingent liabilities, also require judgment and estimations if any. (Refer Note-38)
- V) **Events after the reporting period** - Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are approved by the Board of Directors. These events can be classified as :
- i) **Adjusting Events** those that provide evidence of conditions that existed at the end of the reporting period. There are no such events after the reporting period for the company.

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED ON 31.3.2025

Note No : 4

(Rs.000)												
PROPERTY, PLANT & EQUIPMENT												
Sr No.	Particulars	GROSS BLOCK				Balance As on	DEPRECIATION				NET BLOCK	
		Balance As on	Add: Additions during the year	Add: Additions during the year	Less : Deletion/ Written off/Capital Subsidy during the year		Balance As on	Accumulated Depreciation / Amort. As on	Dep./ Amort. On Opening Balance and addition during the year	Less : Dep. Deletion during the Year/Other adjustment		
											01.04.2024	FIRST HALF
1	Building	95,969.61	64,304.84	0.00	-20,264.66	140,009.79	35,758.88	4,567.80	680.01	39,646.66	100,363.13	60,210.73
2	Plant and Equipment	76,349.32	61,337.36	23,427.08	-6,322.97	154,790.79	36,144.17	7,120.34	105.85	43,158.65	111,632.14	40,205.15
3	Electrical Installation	8,132.93	9,352.44	3,833.37	0.00	21,318.73	6,565.34	1,219.32	0.00	7,784.66	13,534.07	1,567.59
4	VEHICLES	3,430.36	167.38	0.00	0.00	3,597.74	2,078.40	426.07	0.00	2,504.46	1,093.28	1,351.97
5	FURNITURE	4,470.66	178.82	147.25	0.00	4,796.74	2,041.47	390.90	0.00	2,432.37	2,364.37	2,429.19
6	COMPUTER & ACC	754.10	140.65	54.93	0.00	949.68	569.13	151.70	0.00	720.83	228.86	184.97
7	OFFICE EQUIPMENT	3,648.36	304.52	211.67	0.00	4,164.56	2,365.92	413.50	0.00	2,779.42	1,385.14	1,282.45
	Total	192,755.34	135,786.01	27,674.31	-26,587.63	329,628.03	85,523.30	14,289.62	785.86	99,027.06	230,600.97	107,232.04
	Previous Year	163,552.46	805.02	524.27	-1,324.90	163,556.85	70,567.62	7,489.79	-824.90	77,232.51	86,324.34	92,984.83

(Rs.000)												
		INTANGIBLE ASSETS										
		GROSS BLOCK				AMORTISATION				NET BLOCK		
Sr. No.	Particulars	As at 1 st April, 2024	Additions During the Year	Adjustment/ Deduction during the Year	As at 31 st March, 2025	As at 1 st April, 2024	During the year	Adjusted with Retained Earnings during the year	Less : Dep. Deletion during the Year/Other adjustment	Upto 31 st March, 2025	As at 31 st March, 2025	As at 31 st March, 2024
1	Computer software (Acquired)	6.95	-	-	6.95	6.85		0.00	0.00	6.85	0.10	0.10
		6.95	0.00		6.95	6.85	0.00	0.00	0.00	6.85	0.10	0.10
	Previous Year	6.95		-	6.95	6.85	0.00	0.00	0.00	6.85	0.10	0.10

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
NOTE - 4 A
Capital Work In Progress
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Projects Work In Progress				
- less than 6 months	85,055.74		101,419.83	
- 1 year to 2 years	0.00		0.00	
- 2 year to 3 years	0.00		0.00	
- More than 3 years	0.00	85,055.74	0.00	101,419.83
		85,055.74		101,419.83

NOTE - 5
Non-current investments
(Rs. 000)

Particulars	Number of	As at 31st	Number of	As at 31st
	Shares/ units	March, 2025	Shares/ units	March, 2024
Other Investments :				
(1) Designated at fair value through profit or loss:				
(i) Quoted				
(a) In equity shares of Companies at cost fully paidup	-	-	-	-
(b) In units of mutual fund	-	-	-	-
(ii) Unquoted **				
(a) In equity shares of Companies at cost fully paidup	72.71	727.10	72710	727.10
(b) In others	-	3.00	-	3.00
		730.10		730.10

****Unquoted Shares**

The Company is having Equity Shares Shree Malwa Plastic Packaging Cluster Private Limited 72710 Nos (72710 nos.) of Equity Shares of Rs. 10 Face Value each which is valued at cost.

Note No : 6
Other financial assets - Non current (Unsecured considered good)
(Rs. 000)

Particulars	31.03.2025	31.03.2024
Right of Use Asset	6,217.97	1,543.63
	6,217.97	1,543.63

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 7
Other non-current assets (Unsecured considered good)
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Capital advances	29,814.74		3,573.09	
Loans & Advances:-Loans to Related Parties *	29,686.52		10,134.29	
Fair Value of Plan Assets (Gratuity)	2,293.49		2,293.49	
Remeasurement of Gratuity	0.00		987.25	
		61,794.75		16,988.12
		61,794.75		16,988.12

* Refer Note number 34

Note No : 8
Inventories
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Raw materials	46,915.79		58,040.59	
Raw materials in transit	1,010.00		0.00	
Packing materials	0.00		217.83	
Work-in-progress	0.00		113.69	
Finished goods	33,496.55	81,422.34	26,266.32	84,638.43
Total		81,422.34		84,638.43

Note No : 9
Trade receivables - Current
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Unsecured, considered good				
Trade Recivable, considered good-secured	0.00		0.00	
Trade Recivable, considered good-Un secured	166,768.58		79,277.48	
Trade Recivable, Which have Significant Increase in Credit Risk	2,045.76		1,878.10	
Less : Provision for Doubtful Debt	-1,862.76		-2,262.76	
Trade Receivables- Credit Impaired	0.00	166,951.58	0.00	78,892.82
Total		166,951.58		78,892.82

Ageing for trade receivable from the due date of Payment for each of the category as at 31st March, 2025 is as follows

Particulars	Less than 6 months	6 months year	1-2 year	2-3 years	More than 3 years	Total
Undisputed trade Receivables, considered good	166,527.30	0.00	27.72	-	-	166,555.03
Undisputed trade Receivables which have significant increase in Credit Risk	-	-	115.97	542.29	1,387.50	2,045.76
Undisputed trade - Credit Impaired	-	-	-	-	0.00	0.00
Disputed unsecured, considered good	-	-	-	-	-	0.00
Disputed trade Receivables which have significant increase in Credit Risk	-	-	-	-	-	0.00
Disputed trade - Credit Impaired	-	-	-	-	-	0.00
Total (A)	166,527.30	0.00	143.69	542.29	1,387.50	168,600.78

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025

Ageing for trade receivable from the due date of Payment for each of the category as at 31st March, 2024 is as follows

Particulars	Less than 6 months	6 months year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade Receivables, considered good	79,146.39	131.09	0.00	0.00	0.00	79,277.48
Undisputed trade Receivables which have significant increase in Credit Risk	-	-	542,293	91.54	1,244.27	1,878.10
Undisputed trade - Credit Impaired	-	-	-	-	-	0.00
Disputed unsecured, considered good	-	-	-	-	-	0.00
Disputed trade Receivables which have significant increase in Credit Risk	-	-	-	-	-	0.00
Disputed trade - Credit Impaired	-	-	-	-	-	0.00
	79,146.39	131.09	542.29	91.54	1,244.27	81,155.58

Note No : 10
Cash and cash equivalents
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Balances with banks				
In current accounts	514.94		281.78	
Cash on hand	1.19	516.13	39.35	321.13
Total		516.13		321.13

Note No : 11
Bank balances other than cash and cash equivalents
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Fixed deposits with banks				
- Current portion of original maturity period more than 12 months	132.70		132.70	
- Original maturity period upto 12 months	0.00	132.70	0.00	132.70
Total		132.70		132.70

Note No : 12
Other current assets
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
(Unsecured, considered good)				
Other Loans & Advances				
Advance to Suppliers	4,665.66		1,528.18	
Advance to Employees	647.04		327.08	
GST Receivables	26,338.82		9,523.84	
VAT & Other Receivables	94.50		94.50	
TDS Receivables	1,412.15		364.41	
Advance Income Tax	7,900.00		5,628.75	
Prepaid Expenses	896.23		1,175.55	
Security Deposit	5,207.00		2,313.18	
Export incentive receivable	0.00	47,161.40	0.00	20,955.48
		47,161.40		20,955.48

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 13
Equity Share capital
(Rs. 000)

NAME OF SHAREHOLDER	As at 31.03.2025		As at 31.03.2024	
	No. of Shares	Amount	No. of Shares	Amount
(a) Authorised				
15,000,000 Equity Shares of Rs. 10 each	15000000	150,000.00	12250000	122,500.00
[Previous Year 12,250,000 Equity Shares of Rs. 10 each]				
		150,000.00		122,500.00
(b) Issued, subscribed and fully paid up				
10,937,612 Equity Shares of Rs. 10 each at the beginning of the year [Previous Year 10937612 Equity Shares of Rs. 10 each]	10937612	109,376.12	10937612	109,376.12
2275000 Preferential Shares of Rs. 10 each	2,275.00	22,750.00	0.00	0.00
[Previous Year NIL]				
Less :Calls In Arrear		340.00		340.00
Changes during the year		0.00		0.00
At the end of the year		131,786.12		109,036.12

- (c) The Company has only one class of equity shares having a par value of Rs 10/- per share. Each holder of equity shares is entitled to one vote per share. The holders of Equity Shares are entitled to receive dividends as declared from time to time. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. Further, during the year the Board of Directors of the Company in its meeting held on May 6, 2024 has allotted 2275000 Fully paid up equity shares of Rs.10 each at a premium of Rs.34 per share on Preferential Basis to Promoter Group and other non promoter group in accordance with provisions of Chapter V of SEBI (ICDR) Regulations, 2018.

(d) Shareholders holding more than 5 % of the equity shares in the Company :

NAME OF SHAREHOLDER	As at 31.03.2025		As at 31.03.2025	
	No of Shares held	% of Holding	No of Shares held	% of Holding
M/s Sushen Remedies Pvt. Ltd.	2529307	19.14%	2529307	23.12%
Mr. Anand Bangur	1484028	11.23%	1150028	10.51%
M/s Baldeo Mangilal (HUF)	2118661	16.04%	2118661	19.37%
Mr. Vishnu Jajoo	811900	6.14%	477900	4.37%
M/s Vyanktesh Securities IMF Private limited	560500	4.24%	560500	5.12%
		56.80%		62.50%

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025

(e) Shares held by the promoters at the end of the year

NAME OF SHAREHOLDER	As at 31.03.2025		As at 31.03.2024	
	No of Shares held	% of Total Share	No of Shares held	% of Total Share
M/s Sushen Remedies Pvt. Ltd.*	2529307	19.14%	2529307	23.12%
Mr. Anand Bangur**	1484028	11.23%	1150028	10.51%
Mr. Arpit Bangur**	334000	2.53%	-	-
Mrs. Samiksha Bangur**	334000	2.53%	-	-
Mrs. Mangla Bangur**	334000	2.53%	-	-
M/s Baldeo Mangilal (HUF)**	2118661	16.04%	2118661	19.37%
M/s Vyanktesh Securities IMF Private limited**	560500	4.24%	560500	5.12%
M/s Arpit Packaging Private Limited**	495600	3.75%	495600	4.53%
Mrs. Shweta Jajoo**	479936	3.63%	479936	4.39%
Mr. Vishnu Jajoo**	811900	6.14%	477900	4.37%
Mr. Brahma Swaroop Jajoo**	194700	1.47%	194700	1.78%
Mrs. Krishna Jajoo**	26993	0.20%	26993	0.25%

* Promoter

** Promoter Group.

Note No : 14 Other equity

(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2025	
(a) Capital Reserve	2,500.00		2,500.00	
(b) Investment Allowance reserve	4,230.75		4,230.75	
(c) General Reserve	0.00		0.00	
(d) Securities Premium	99,802.25	106,532.99	22,452.25	29,182.99
(d) Retained earnings				
Balance as per Last Account	-29,851.94		-63,304.90	
Add : Surplus as per Statement of Profit and Loss	60,687.05		33,452.96	
Other Comprehensive Income(net of tax)	0.00		0.00	
Amount available for appropriation	30,835.11		-29,851.94	
Less : Appropriations:				
Transfer to general reserve	0.00		0.00	
Balance at the end of the year		30,835.11		-29,851.94
Total other equity		137,368.10		-668.95

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 15
Non-Current financial Liability
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Long Term Borrowings- Secured				
(i) From Banks	143,716.74		112,506.53	
Long Term Borrowings- Un Secured				
(i) From Inter Corporate Deposits	0.00		25,937.17	
		143,716.74	0.00	138,443.71
		143,716.74		138,443.71

* Refer Note No. 15A

Note No : 15A
1) Securites provided towards secured loans;

- i) Term Loan From HDFC Bank Loan Account No: 85921402 , For Total Tenure - 64 Months , Total Amount Financed- 29,718.567 Thousands Out of which Amount Disbursed-29,526.431 Thousands Payable In Monthly Installments of Rs 614,821/- (including interest) Commencing From 07/12/2021. Installments Falling Due in respect of the above loan upto 31.03.2026 have been grouped under "Short Term Borrowings' (Refer Note no. 16)
- ii) Term Loan From HDFC Bank Loan Account No: 86797539 , For Total Tenure - 63 Months ,Total Amount Financed- 15,000.000 Thousands Out of which Amount Disbursed- 14,955.042 Thousands Payable In Monthly Installments of Rs 304,146/- (including interest) Commencing From 07/08/2022. Installments Falling Due in respect of the above loan upto 31.03.2026 have been grouped under "Short Term Borrowings' (Refer Note no. 16)
- iii) Term Loan From HDFC Bank Loan Account No: 89767084 , For Total Tenure - 84 Months ,Total Amount Financed- 73,934.828 Thousands Out of which Amount Disbursed- 73,934.828 Thousands Payable In Monthly Installments of Rs 1,308,565/- (including interest) Commencing From 07/04/2024. Installments Falling Due in respect of the above loan upto 31.03.2026 have been grouped under "Short Term Borrowings which is duly been updated as and when amount disbursed(Refer Note no. 16)
- iv) Term Loan From HDFC Bank Loan Account No: 89458829 , For Total Tenure - 84 Months ,Total Amount Financed- 30,400.583 Thousands Out of which Amount Disbursed- 30,400.583 Thousands Payable In Monthly Installments of Rs 550,055/- (including interest) Commencing From 07/02/2024. Installments Falling Due in respect of the above loan upto 31.03.2026 have been grouped under "Short Term Borrowings which is duly been updated as and when amount disbursed(Refer Note no. 16)
- v) Term Loan From HDFC Bank Loan Account No: 86959376 , For Total Tenure - 61 Months ,Total Amount Financed- 20,600.000 Thousands Out of which Amount Disbursed- 20,600.000 Thousands Payable In Monthly Installments of Rs 64,316/- (including interest) Commencing From 07/06/2022. Installments Falling Due in respect of the above loan upto 31.03.2026 have been grouped under "Short Term Borrowings' (Refer Note no. 16)
- vi) Term Loan From Bank Of Baroda Bank , For Total Tenure - 84 Months ,Total Amount Financed- 97,700.000 Thousands Out of which Amount Disbursed- 73,015.275 ,Payable In Monthly Installments of Rs 10,00,000/- (excluding interest) Commencing From 07/04/2025. Installments Falling Due in respect of the above loan upto 31.03.2026 have been grouped under "Short Term Borrowings' (Refer Note no. 16)

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 16
Short - Term borrowings
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
<u>Other Loans</u>				
From banks - Secured				
(i) From Banks	33,795.54		16,522.52	
(Installments of Term Loan repayable within 12 Months)				
Bank Overdraft				
(HDFC Bank CC A/c (Working Capital limit)	167,546.02	201,341.56	103,744.48	120,267.00
(No Overdraft against the existing sanctioned CC Limit)				
		201,341.56		120,267.00

* Refer Note No. 15A

Note No : 17
Trade Payables - Current
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
<u>Total outstanding dues of micro enterprises and small enterprises</u>				
Creditors for Goods	768.01		612.13	
Creditors for services	0.00	768.01	316.23	928.37
<u>Total outstanding dues of creditors other than micro enterprises and small enterprises</u>				
Creditors for Goods	40,160.02		5,043.81	
Creditors for Services	2,001.69	42,161.70	1,139.64	6,183.45
		42,929.71		7,111.81

Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006 Particulars Trade Payables

(Rs. In 000)

Particulars	As at 31.03.2025	As at 31.03.2024
A (i) Principal amount remaining unpaid	768.01	612.13
A (ii) Interest amount remaining unpaid	-	-
B) Interest Paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act 2006 Along with the Amount of the Payment Made to the Suppliers Beyond the appointed date	-	-
C) Interest Due and Payable for the Period of Delay in Making Payment (Which Have been paid but beyond the appointed day during the period) but without adding Interest specified under the Micro, Small and Medium Enterprises Act, 2006	-	-
D) Interest Accrued and remaining paid	-	-
D) Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	-	-
TOTAL	768,009	612.13

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025

Ageing for trade Payables from the due date of Payment for each of the category as at 31st March, 2025 is as follows

Particulars	outstanding for following Periods from due date of payment					
	Less than 6 months	6 months year	1-2 years	2-3 years	More than 3 years	Total
Sundry Creditors for Goods *	40,160.02	-	-	-	-	40,160.02
Sundry Creditors for Services *	2,001.69	-	-	-	-	2,001.69
Total (A)	42,161.70	0.00	0.00	0.00	0.00	42,161.70

Ageing for trade Payables from the due date of Payment for each of the category as at 31st March, 2024 is as follows

Particulars	outstanding for following Periods from due date of payment					
	Less than 6 months	6 months year	1-2 years	2-3 years	More than 3 years	Total
Sundry Creditors for Goods *	5,972.18	-	-	-	-	5,972.18
Sundry Creditors for Services *	1,139.64	-	-	-	-	1,139.64
Total (A)	7,111.81	0.00	0.00	0.00	0.00	7,111.81

Note No : 18
Other financial liabilities - Current
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
<u>Other payables</u>				
Payable to suppliers of capital goods	4,352.51		201.54	
Outstanding Liabilities for Expenses	2,714.65		3,044.72	
		7,067.15		3,246.26
		7,067.15		3,246.26

Note No : 19
Current provisions
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Provision for Income Tax	8,819.56		6,701.84	
Provision for Employee Exp	7,320.25		6,165.05	
Provision for Audit Fees	104.25		54.00	
Provision for Director Sitting Fees	0.00	16,244.05	13.00	12,933.89
		16,244.05		12,933.89

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 20
Other current liabilities
(Rs. 000)

Particulars	As at 31.03.2025		As at 31.03.2024	
Advance Received	468.59		14,762.07	
Statutory liabilities	10,618.02	11,086.60	498.70	15,260.77
Total		11,086.60		15,260.77

Note No : 21
Revenue From Operations
For the Year Ended (Rs. 000)

Particulars	As at 31.03.2025	As at 31.03.2024
Sale Of Goods	606,752.15	432,488.09
Sale Of Trading	17,452.27	
	624,204.43	432,488.09

Note No : 22
Other Income
For the Year Ended (Rs. 000)

Particulars	As at 31.03.2025	As at 31.03.2024
Interest Income		
Interest On Security Deposit	1,748.76	160.81
Other Interest	0.00	343.66
Trade Discount	0.50	36.02
Exchange Fluctuation	12.14	11.57
Other Income	228.59	50.14
Total	1,989.98	602.19

Note No : 23
Cost of Material Consumed
For the Year Ended (Rs. 000)

Particulars	As at 31.03.2025	As at 31.03.2024
Opening Stock of Raw Material and Consumables	58,258.42	52,067.82
<u>Purchases and Incidental Expenses</u>		
Purchase With in State	393,130.00	297,422.30
Purchase Out of State	3,148.61	12,135.04
Import Purchase	19,402.41	
Exp on Purchase (Incidental to Purchase)	4,290.01	1,585.26
<u>LESS:</u>		
Discount & Rate Diff.	0.00	-1.05
Closing Stock of Raw Material and Consumables	-47,925.79	-58,258.42
	430,303.65	304,950.96

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 24
Changes in Inventory of Finished goods, Work in Progress & Stock-in-Trade

Particulars	For the Year Ended (Rs. 000)	
	As at 31.03.2025	As at 31.03.2024
(Increase) / Decrease in Stocks		
Stock at the Beginning of the year	26,380.01	14,042.19
Finished Goods		
TOTAL (A)	26,380.01	14,042.19
Less: Stock at the End of the year	33,496.55	26,380.01
Finished Goods		
TOTAL (B)	33,496.55	26,380.01
TOTAL (A-B)	-7,116.54	-12,337.82

Note No : 25
Employee Benefit expenses

Particulars	For the Year Ended (Rs. 000)	
	As at 31.03.2025	As at 31.03.2024
Salaries & Wages	34,770.89	28,460.44
Contribution to Provident & Other Funds	2,618.66	3,005.78
Bonus	1,294.59	697.09
Staff Welfare Expenses	509.50	312.01
	39,193.64	32,475.31

Note No : 26
Finance Costs

Particulars	For the Year Ended (Rs. 000)	
	As at 31.03.2025	As at 31.03.2024
Interest Expenses	19,925.16	14,188.96
Other Borrowing Costs	192.43	172.60
Interest Exp on DBO	258.88	372.72
Bank Charges	904.29	921.90
	21,280.74	15,656.18

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
Note No : 27
Other Expenses

Particulars	For the Year Ended		(Rs. 000)
	As at 31.03.2025	As at 31.03.2024	
<u>MANUFACTURING, OFFICE AND ADMINISTRATION EXPENSES</u>			
<u>MANUFACTURING EXPENSES</u>			
Factory exp	1,677.74	947.34	
Factory Labour Charges	10,759.20	3,802.62	
Job Work Charges	0.00	47.66	
Machinery Maintenance Exp	3,480.83	1,716.54	
Power Charges	24,135.35	17,050.56	
Water Charges	175.60	122.50	
Total (a)	40,228.73	23,687.23	
<u>SELLING EXPENSES</u>			
Advertisement & Publicity	316.64	150.69	
Commission	78.71	198.22	
Freight on Sales	11,628.36	8,840.82	
Loading and Unloading	7.80	53.50	
Rate Discount	7.36	122.61	
Testing charges	280.60	380.53	
Travelling Expenses	436.97	299.95	
Total (b)	12,756.44	10,046.32	

<u>OFFICE AND ADMINISTRATION EXPENSES</u>			
Annual Listing Charges	610.00	370.00	
BIS EXP	32.00		
Audit Fees	225.00	190.00	
Conveyance Exp	378.24	360.63	
Consultancy Charges	0.00	68.89	
Director Sitting Fees	102.00	107.00	
Doubtfull Debt	170.97	589.78	
Factory Licence Fee	91.34	159.68	
Insurance Exp.	421.79	387.06	
Legal & Professional Expense	1,466.21	1,378.11	
Membership Fees	6.50	11.92	
Maintenance Exp	1,658.96	931.73	
Office Exp	17.76	167.93	
Printing and Postage	747.98	603.85	
Rates and Taxes	43.69	155.64	
Refreshment Exp	243.27	115.28	
Telephone Exp	96.18	93.89	

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025

Security Exp	1,907.03	1,218.50
Sundry Balance Written off	-1,125.14	-134.16
Vehicle Rent	756.00	576.00
Website Charges	35.00	0.00
Total (c)	7,884.79	7,351.73
Grand Total (a+b+c)	60,869.96	41,085.28

Note No : 28
Exceptional Items
For the Year Ended (Rs. 000)

Particulars	As at 31.03.2025	As at 31.03.2024
Other Expenditure	0.00	0.00
	0.00	0.00

Note No : 29
Other comprehensive income
For the Year Ended (Rs. 000)

Particulars	As at 31.03.2025	As at 31.03.2024
<u>Items that will not be reclassified to profit or loss</u>		
Re- measurement of defined benefit plans	-625.39	167.64
Less: Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
	-625.39	167.64

30. Earning Per Share (EPS)

Particulars	Year Ended	
	March 31, 2025	March 31, 2024
Net Profit after tax as per Statement of Profit and Loss attributable to Equity Shareholders	6,06,87,050	3,34,52,964
Weighted Average number of equity shares used as denominator for calculating EPS	1,31,78,612	1,09,03,612
Basic and Diluted Earnings per share	4.60	3.07
Face Value per equity share	10	10

- 31. Segment Reporting** - The principal business of the company is manufacturing and sale of Plastics bottles, caps, Plastic liners, Sanitary Napkins, Adult Diapers & related products. All other activities are ancillary to the main activities. Operating segment is reported in a manner consistent with the internal reporting provided to Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance, allocates resources based on analysis of the various performance indicators of the Company as a single unit. CODM have concluded that there are 2 operating reportable segments as defined by Ind AS 108, i.e. Plastic segment & Hygiene Segment.

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
A) Information about revenue from external customers
(Rs. In '000)

Particulars	Revenue from customers	
	2024-25	2023-24
The Company operates within:		
1. Plastic Segment	559007.55	432488.09
2. Hygiene Segment	113727.22	-

(The values include inter segment revenue)

B) Information about major customers
(Rs. In '000)

Particulars	Net Revenue	
	2024-25	2023-24
M/s Shriniwas Polyfabric & Packwell Pvt Ltd	90688	59869
M/s Shriji Polymers India Limited	81830	74736
M/s Sudarshan Pharmaceuticals Pvt Ltd	47003	-
M/s Nipro India Corporation Pvt Ltd	42983	19699
M/s Dabur India Limited	38957	39366
M/s Alembic Pharmaceuticals Ltd	29813	22375
M/s Tatva the Life	25026	-
M/s Shree Baidyanath Ayurved Bhawan Pvt Ltd	23646	2124
M/s IOL Chemicals & Pharmaceuticals Ltd	19236	20201
M/s Zydus Lifesciences Ltd	19152	8648
M/s Cipla Ltd	16602	13660
M/s Sandoz Private Limited	11026	12172

(Note: Revenue is net from credit notes & excluding taxes)

31A. The details of immovable property whose title deeds are not held in the name of the company.

Relevant Line Item in the Balance Sheet	Description of Items Of Property	Gross Carrying Value	Title Deeds held in the name of	Whether Title deed holder is a promoter/ director, OR relative of Promoter/ Director OR employee of promoter/direct	Property Held since which date	Reason for not being held in the name of the company
NIL						

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
32. Employee Benefits: -
a) Defined contributions plans –

Amount recognized and included in Note-25 as “PF& ESI Contribution (Employer)” of statement of profit and loss Rs.2618.66 Thousand (previous year Rs. 3005.78 Thousand).

b) Defined benefit plans –

Funded gratuity plan (LIC New Group Gratuity Cash Accumulation Plan) is accounted for on accrual basis. The company is in process to calculate the past service cost/Liability with a Life Insurance corporation of India to that extent the liability is undervalued and amount is unascertainable in absence of actuarial figures. Although for Leave Encashment benefits are accounted for on cash basis, its effect on Statement of Profit and Loss of the company is not determined.

33. Amount paid to Auditors
(Rs. In ‘000)

Particulars	2024-25	2023-24
Audit Fees	219.95	190.00
(Note: fees are excluding of GST)		

34. Related Party Disclosures:
A) Related parties
a) Key Managerial Personnel (KMP)

Sr.	Name of the related parties	Nature of Relationship
i)	Mr. Arpit Bangur	Managing Director
ii)	Mr. Navin Jhawar	Jt. Managing Director
iii)	CA Ankita Jain	Chief Financial Officer
vi)	CS Sachin Sarda	Company Secretary

a) Related parties with whom transactions have taken place during the year

Sr.	Name of the related parties	Relationship
1	M/s Shriniwas Polyfabrics and Packwell Private Limited	Shri Arpit Bangur and his relatives are shareholders
2	M/s Shriji Polymers India Limited	Shri Arpit Bangur through is relatives
3	M/s Shree Packers (M.P.) Private Limited	Shri Arpit Bangur is a Director
4	M/s Arpit Plastic Private Limited	Shri Arpit Bangur and his relatives are Shareholders
5	M/s Ariba Foods Private Limited	Shri Arpit Bangur is a Director
6	M/s Patni Industries Limited	Shri Arpit Bangur is a Director
7	M/s Narsingh Transport	Shri Arpit Bangur is a Partner
8	M/s Vyanktesh Corrugators Private Limited	Shri Arpit Bangur through his relatives
9	M/s Dwarkesh Finance Limited.	Shri Arpit Bangur is a director and relatives are shareholders
10	M/s Four M Propack Pvt Limited	Shri Arpit Bangur through his relatives
11	M/s Tirupati Corrugators	Shri Arpit Bangur through his relative is partner
12	M/s Vyanktesh Plastic and packaging pvt ltd	Shri Arpit Bangur through his relatives
13	M/s Parekh Plast India Limited	Shri Arpit Bangur through his relatives
14	M/s Ujjain Security and Manpower Services Pvt. Ltd	Shri Hemant Kasliwal is a Director.

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
B) Details of Related party transactions
(Rs. in '000)

Sr.	Particulars	31.03.2025	31.03.2024
1.	Transactions with Key Managerial Personnel (KMP):		
	a) Remuneration & Other Reimbursement		
	Shri Navin Jhawar	2478.00	2109.20
	CA Ankita Jain	653.28	581.42
	CS Sachin Sarda	378.00	349.92
	Mrs. Shweta Jajoo	1260.00	1269.20
	Mr. Arpit Bangur	3000.00	0
	b) Directors Sitting Fees	102.00	107.00
2.	Transactions with Related Parties:		
	a) Purchase of goods		
	M/s Shriji Polymers India Ltd.	4444.80	2671.42
	M/s Vyanktesh Corrugators Pvt. Ltd.	1529.73	1320.69
	M/s Arpit Plastic Pvt Ltd	1391.48	671.45
	M/s Shree Packers (MP) Pvt. Ltd.	2240.75	2382.68
	M/s Four M Propack Pvt. Ltd.	3849.28	7.75
	M/s Shriniwas Polyfabrics & Packwell Pvt. Ltd.	8422.23	0
	b) Interest Expenditure		
	M/s Shriniwas Polyfabrics & Packwell Pvt. Ltd.	24.82	15.98
	M/s Dwarkesh Finance Ltd	124.70	1658.36
	M/s Patni Industries Ltd.	41.57	371.07
	c) Other Recoveries		
	M/s Shriniwas Polyfabrics & Packwell Pvt. Ltd.	1502.47	-
	d) Other Expenses		
	M/s Ariba Foods Pvt Ltd	180.41	84.65
	M/s Arpit Plastics Pvt Ltd	-	-
	M/s Narsingh Transport	2441.1	2609.00
	M/s Ujjain Security and Manpower Services P Ltd	653.23	-
	M/s Four M Propack Pvt. Ltd.	35.4	-
	e) Inter Corporate Loans taken - balance outstanding at year end		
	M/s Dwarkesh Finance Ltd	-	19452.38
	M/s Patni Industries Ltd.	-	6484.79
	M/s Arpit Plastic Pvt. Ltd	-	-
	f) Sales		
	M/s Shriji Polymers India Ltd.	96477.45	88174.29
	M/s Shree Packers (MP) Pvt. Ltd.	7516.97	7810.73
	M/s Arpit Plastic Pvt. Ltd	1449.53	4187.16

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025

M/s Four M Propack Pvt Ltd	7981.02	2791.20
M/s Ariba Foods Pvt. Ltd	-	-
M/s Vyanktesh Corrugators Pvt. Ltd	436.03	234.22
M/s Shriniwas Polyfabrics & Packwell Pvt. Ltd.	100777.29	70645.04
M/s Shriniwas Pharmachem Pvt. Ltd.	-	9.71
M/s Parekh Plast India Limited	8756.94	-
g) Inter Corporate Loans given - balance outstanding at year end		
M/s Shriniwas Polyfabrics & Packwell Pvt. Ltd.	29686.52	10134.29
h) Purchase of fixed assets		
M/s Arpit Plastic Pvt. limited	248.50	-
M/s Four M Propack Pvt. Limited	13704.52	-
M/s Shriji Polymers India limited	953.14	-
i) Sale of fixed assets		
M/s Vyanktesh Plastic and Packaging Pvt. ltd	6000	-

35. Disclosures about Trade payables:

Based on the information available with the Company, the details of amounts outstanding to Micro, Small and Medium Enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) are as under:

(Rs. in '000)

Particulars	As at March 31,2025		As at March 31,2024	
	Principal	Interest	Principal	Interest
Amount Due to Vendor	768.01	-	928.37	-
Principal amount paid (includes unpaid) beyond the appointed date	0.00	-	0.00	-
Interest Due & Payable during the year		-*		-*
Interest Accrued & remaining Unpaid		-*		-*

*Interest payable on the amount unpaid beyond the appointed date has not been recognized by the Company.

Dues to MSME have been determined to the extent such parties have been identified on the basis of information collected by the management. Since, there is no facility to identify registration and status of payee. Further, an MSME form 1 is not filed as there is no overdue MSME with the company.

36.Earning and expenditure in Foreign Currency:

(₹ In '000)

Particulars	2024-25	2023-24
Earning in Foreign Currency	232.185	86.62
Expenditure in Foreign Currency	NIL	NIL

RAAJ MEDISAFE INDIA LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025
37. Ratio Analysis

Ratio	FY 2024-25	FY 2023-24	Variance	Reason
Current Ratio	1.21	1.30	7%	
Debt-Equity Ratio	0.66	1.43	54%	Increase in Equity is substantially more than increase in Total Debt
Debt Service Coverage Ratio	1.61	2.08	23%	
Return on Equity Ratio	32.15	36.50	12%	
Inventory Turnover Ratio	5.10	3.88	31%	Inventory purchased has increased proportionately more than increase in Average inventory held
Trade Receivables Turnover Ratio	5.08	5.40	6%	
Trade Payables Turnover Ratio	16.78	41.68	60%	The average trade payables have increased more than 3 times while the net purchases increased only by around 30%
Net Capital Turnover Ratio	12.17	10.14	20%	Due to increase in working capital significantly as compared to sales
Net Profit Ratio	0.10	0.08	26%	
Return on Capital Employed	11.82	13.55	13%	Substantial Increase in Deferred Tax income increased net profit for the current year

*Note: -The Ratio is being calculated on the basis of the software maintained by the Company. The management & Auditors is relied on the same.

37-A Beneficiaries disclosures

- No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- No funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

38. Contingent Liability and Capital Commitments:
a) Direct tax (Income Tax)

For AY 2018-19, Assessment order U/s 143(3) was issued by ACIT, Income Tax, Central, Ujjain on 05.04.2021 making addition of Rs. 35,70,826/-The said order was appealed to CIT (A) on 24.04.2021.

- Company's Capital Commitments for the year is Rs.30.10 Crores.

39. Other Disclosures:

- Accounts statements of in-operative bank accounts held in the name of the company are not available hence

RAAJ MEDISAFE INDIA LIMITED**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED ON 31.03.2025**

balances in such accounts are subject to confirmation.

- d) Balances of trade receivables, trade payables and loans & advances are subject to confirmation.
- e) GST Credits and inputs are subject to reconciliation. The Concerned Statutory Form with respective department were file as and when due for filing.
- f) Relationship with Struck off Companies - The Company does not have any transactions or relationships with any companies struck off under Section 248 of the Companies Act, 2013.
- g) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- h) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2025 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made there under.
- i) There are no charges or satisfaction of charges yet to be registered with Registrar of Companies beyond the statutory period.
- j) There are no transactions that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 which have not been recorded in the books of account.
- k) The Company has not traded or invested in Virtual Currency.
- l) The Ministry of Corporate Affairs (MCA) has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted by the Companies (Accounts) Amendment Rules 2021 requiring companies, which uses accounting software for maintaining its books of accounts, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of accounts along with the date when such changes were made and ensuring that the audit trail cannot be disabled.
- m) Company not falls under the provision of section 135 Of the companies Act, 2013 i.e. CSR Provision
- n) Previous year figures have been rearranged / regrouped where ever necessary to confirm to current year's classification.

As per our report on even date

For V.K.Ladha & Associates

Chartered Accountants

Firm Regn. No. 002301C

For and on behalf of Board of Directors

For Raaj Medisafe India Limited

Sd/-
Arpit Bangur
Managing Director
(DIN-02600716)

Sd/-
Navin Jhavar
Jt. Managing Director
(DIN-08729821)

Sd/-
Hemant Kasliwal
Chairman - Audit Committee
(DIN-01797300)

Sd/-
CA. V. K. Ladha
Membership No. 071501
25071501BMIFZF7727

Sd/-
Ateet Agarwal
Director
(DIN-05167866)

Sd/-
Rakesh Agrawal
Director
(DIN-09675176)

Sd/-
CA Ankita Jain
Chief Financial Officer
(M.No.426121)

Sd/-
CS Sachin Sarda
Company Secretary
(M. No.20930)

Ujjain, 29th May, 2025

Ujjain, 29th May, 2025